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Directed evolution is a powerful tool to improve the characteristics of biomolecules. Here we 26 
present a protocol for the intracellular evolution of proteins with distinct differences and 27 
advantages to established techniques. These include the ability to select for a particular 28 
function from a library of protein variants inside cells, minimizing undesired co-evolution and 29 
propagation of non-functional library members, as well as allowing positive and negative 30 
selection logics using basally-active promoters. A typical evolution experiment comprises the 31 
following steps: (i) Preparation of a combinatorial M13 phagemid library expressing variants 32 
of the gene of interest and the E. coli host cells; (ii) Multiple rounds of an intracellular 33 
selection process towards a desired activity; (iii) The characterization of the evolved target 34 
proteins. The system has been developed for the selection of new orthogonal transcription 35 
factors1 (TFs) but is capable of evolving any gene – or gene circuit function – that can be 36 
linked to conditional M13 phage replication. Here we demonstrate our approach by the 37 
directed evolution of TFs based on λ cI against two synthetic bidirectional promoters. The 38 
evolved TF variants enable simultaneous activation and repression against their engineered 39 
promoters and do not cross-react with the wild-type promoter, thus ensuring orthogonality. 40 
This protocol requires no special equipment, allowing synthetic biologists and general users 41 
to evolve improved biomolecules within ~7 weeks. 42 
 43 
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EDITORIAL SUMMARY This protocol describes a phagemid-based intracellular evolution 47 
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Directed evolution has emerged as a powerful tool to improve the characteristics of 60 
biomolecules2-4. The approach mimics natural selection to evolve biomolecules towards a 61 
desired activity5. One efficient and commonly-used strategy to achieve this in a laboratory 62 
environment is to employ filamentous bacteriophages such as M13, to link a mutable 63 
genotype to a selectable phenotype. In this way, a number of M13 phage-assisted methods, 64 
such as the widely-used phage display technology6, have been developed and applied to 65 
improve a wide variety of proteins, including antibodies7-9, DNA-binding proteins10,11, and 66 
enzymes12,13. These systems are characterized by an extracellular (in vitro) or intracellular (in 67 
vivo) mode of operation. In vitro systems are generally easier to engineer in terms of 68 
selection stringency adjustments14, but possess certain limitations that can only be overcome 69 
by applying intracellular processes. For example, selection from combinatorial libraries in 70 
vivo ensures compatibility with the host cell machinery. This facilitates the optimization of 71 
synthetic proteins and gene circuits15-17, which ultimately have to function in a host cell 72 
context. In vivo methods promote selection for orthogonality18,19,	– a lack of cross-reactions – 73 
by intrinsically counter-selecting against adverse effects inside the cell. To further broaden 74 
the applications of in vivo directed evolution, we recently developed an M13 phage-based 75 
method1 for the intracellular selection of proteins from combinatorial libraries with distinct 76 
differences and advantages to established techniques. 77 
 78 
Overview of the protocol 79 
This protocol describes a general approach for the directed evolution of proteins from 80 
combinatorial libraries on phagemids (Fig. 1). The selection process takes place inside 81 
E. coli cells by linking the target protein’s activity to conditional phage production, thus 82 
allowing enrichment of functional library members. This is exemplified here by the directed 83 
evolution of orthogonal dual transcription factors (TFs) based on bacteriophage λ cI variants1, 84 
selecting against synthetic promoters. However, the method can be readily adapted for other 85 
target biomolecules (see Applications of the method). A typical evolution experiment 86 
consists of: 1) The preparation of a combinatorial M13 phage library (steps 1-38) and E. coli 87 
host cells (steps 39-47); 2) The selection process towards a desired activity (steps 48-61); 88 
and 3) The characterization of the selected target proteins (steps 62-68) (Fig. 2). 89 
 90 
The system is based on E. coli cultures and three compatible plasmids (available from 91 
Addgene; see MATERIALS). Together, these conditionally produce phage (containing the 92 








always begins with an E. coli culture that contains the first two plasmids: a modified helper 94 
phage plasmid (HP) and an accessory plasmid (AP) (Fig. 3a). The HP provides almost all 95 
that is needed for phage propagation, except for two essential genes (gIII and gVI). 96 
Furthermore, the weak M13 packaging signal (PS) is removed from the original M13KO7 HP 97 
to obtain the final M13KO7-ΔPS-ΔgIII-ΔgVI HP. The second plasmid, AP, contains a 98 
conditional gene circuit that links an inducible input (e.g. a promoter with a novel operator) to 99 
gVI expression. The evolving gene or gene circuit is placed on the third plasmid, termed a 100 
phagemid (PM), which is packaged into an infectious phage particle only when all phage 101 
genes are expressed. The PM contains the second missing gene (gIII) and a combinatorially-102 
randomized gene of interest (GOI) and is provided to the E. coli culture in the form of an 103 
infectious phage library (Fig. 3b). Crucially, our system moves Gene III onto the phagemid 104 
so that phage replication occurs only after initial infection, thus circumventing infection 105 
resistance20,21, and decreasing the chances of propagating non-functional library members 106 
due to multiple infections. A GOI with the desired characteristics upregulates gene VI 107 
expression on the AP, completing the phage life cycle. For example, a randomized TF library 108 
member that activates an artificial promoter upstream of gVI will increase its own phage 109 
production (Fig. 4a). In this way, a protein with novel desired properties can be selected after 110 
several rounds of reinfection. 111 
 112 
Applications of the method 113 
The method has been used to evolve a set of dual activator-repressor switches for 114 
orthogonal logic gates, based on bacteriophage λ cI variants, and multi-input promoter 115 
architectures, and these switches have been successfully applied in downstream synthetic 116 
gene circuits1. In general, the method is capable of evolving any gene – or gene circuit 117 
function – on the phagemid that can be linked to pVI production. This is analogous to 118 
previous uses of phage-assisted continuous evolution (PACE)22 (Fig. 4). With PACE, a wide 119 
range of medically and biotechnologically relevant biomolecules, including polymerases22, 120 
proteases23, genome-editing proteins11 as well as protein-protein interactions24 were linked to 121 
conditional M13 phage propagation. In principle, any application where directed evolution 122 
approaches have been proposed (e.g. biosensors25 or hybrids with chemical evolution26) can 123 
be adapted to this method if the target protein’s activity can be linked to conditional M13 124 
phage production. Although certain applications (e.g. membrane proteins) would be harder to 125 
adapt, which is why other methods such as liposome display27 have been developed. 126 
 127 








Comparison with other methods 129 
Several bacterial directed evolution methods have been developed based on phage 130 
replication22, display technologies6,27-29, genome engineering30, as well as conditional cell 131 
growth31,32. Linking a target protein’s activity to cell growth is a widely-used strategy and is 132 
particularly suitable when the evolving gene directly improves cellular fitness33,34. The use of 133 
bacteriophage offers a convenient way to uncouple the fitness function of a cell with target 134 
protein activity. This is achieved by linking a target gene’s activity to phage replication using 135 
a conditional gene circuit. The main advantage of conditional phage production over display 136 
technologies is the compatibility of target genes or gene circuits with the host cell machinery 137 
as these have to function in a host cell context. In contrast to PACE (which uses gIII as the 138 
sole conditional gene), our phagemid-based approach facilitates the selection of large 139 
combinatorial libraries and enables positive and negative selection logics using promoters 140 
with basal gene expression. Our system also minimizes the undesired co-evolution of phage 141 
genes as only the packaged phagemid is evolving and not the helper phage itself. In 142 
comparison to PACE, the protocol is performed in batch mode and therefore requires no 143 
special equipment for reactor assembly but instead relies on a daily researcher intervention 144 
during selections. Moreover, the batch process facilitates the performance of multiple 145 
selections in parallel, enabling the scalability of each individual selection and easy handling. 146 
Continuous culture evolution systems can suffer from 'phage washout' (loss of phage) when 147 
conditional phage production rates are not compatible with the flow rates. By contrast, batch 148 
modes are not as sensitive to loss of phage. On the other hand, dozens of rounds of 149 
reinfections occur in a single day of PACE whereas our system is currently limited to one 150 
round per overnight cycle. In addition, combinatorial libraries have to be designed and cloned 151 
because, unlike PACE, our system does not include a random mutagenesis plasmid35. This 152 
means that structural information or a partial understanding of how a set of amino acid 153 
changes will affect the target protein’s activity is required to run our system. 154 
 155 
Limitations of the phagemid-based system 156 
The main limitation of the system is the combinatorial size of the library which is linked to 157 
transformation efficiency (106-1010 variants)36. The selection process itself is not limited to a 158 
certain number of gene variants but it has to be noted that the use of larger libraries comes 159 
with the cost of prolonged experiment times. Another limitation can be the linkage of the 160 
target protein’s activity to conditional M13 phage replication as this depends on the individual 161 
protein’s characteristics. This is certainly more complicated for complex proteins such as 162 








bacterial expression over mammalian expression (e.g. protein solubility, disulfide bonds, 164 
posttranslational modifications) need to be considered for individual target proteins. For 165 
instance, our system would need to be adapted to enable the selection of proteins that 166 
require disulfide bonds for proper folding in bacterial cells37. 167 
 168 
Experimental Design 169 
Combinatorial library cloning on phagemid (PM). Choosing which positions to randomize 170 
in the protein of interest is a critical step as this affects the library size, the cloning strategy, 171 
and ultimately the overall selection results. Small libraries with only one or two randomized 172 
positions can easily be obtained by round-the-world PCR whereas bigger libraries require 173 
overlap extension PCR or end-to-end ligation36. Round-the-world PCR means in this context, 174 
that single base pair mutations are inserted into the target region by amplification of the 175 
whole plasmid DNA with randomized primers so that no additional step for plasmid ligation is 176 
required. For round-the-world PCR, both randomized primers must contain the mutations and 177 
bind to the same DNA sequence on opposite strands of the plasmid. Primers are generally 178 
30-60 nucleotides long (N) and contain mutations in the middle of the randomized primers, 179 
flanked with 15-20 bases of correct sequence on both sides. These primers should ideally 180 
have a minimum GC content of 40% (%GC), end with one or more C or G bases and are 181 
purified by polyacrylamide gel electrophoresis (PAGE). The annealing region should have a 182 
melting temperature (Tm) of ≥78°C using the following formula: Tm = 81.5 + 0.41(%GC) - 183 
675/N - %mismatch. In this protocol, we focus on an overlap PCR approach prior to Gibson 184 
Assembly38 as this has been our method of choice for building λ cIopt libraries with a 185 
combinatorial space of >106 variants (Fig. 5a). These libraries are based on a λ cI optimized 186 
mutant (cIopt) with a strong activation region39. The protocol presented here is optimized for 187 
the construction of combinatorial libraries using Gibson Assembly. It is our method of choice 188 
because it bypasses the need for restriction sites inside target genes which makes it much 189 
easier to construct sequence-targeted libraries. However, the selection system itself is 190 
compatible with any other library generation method36,40 as long as our phagemid vector 191 
backbone is used. The design of randomized oligonucleotides for overlap PCR is similar to 192 
conventional Gibson primer design38. Briefly, PCR primers for insert amplification require a 193 
15-25 bp overlap with each other, as well as a 15-25 bp overlap with the amplified PM vector 194 
backbone. Randomized positions should be avoided in the annealing regions and primers 195 
should ideally have a Tm of 50-60°C using the following formula: Tm = 4(G + C) + 2(A + T) 196 
(where A, C, G and T are the numbers of each base in the primer). The temperature 197 
difference of the primer pairs should be matched and lie within a 5°C range. The maximum 198 








oligonucleotides are sufficiently pure). For evolving a novel protein, the user should ideally 200 
start with a crystal structure of the target molecule (if available) and randomize positions 201 
known to affect the desired activity (e.g. change positions of the binding interface in order to 202 
alter the protein binding interaction). In other cases, biochemical information might also be 203 
sufficient to guide library construction. 204 
Accessory plasmid (AP) design. The conditional gene circuit that links an inducible input to 205 
gVI expression has to be adapted to individual needs. This is achieved by replacing the λ 206 
PRM promoter (pJPC12-ΔPS-PRM-B0034-gVI) with a different promoter or inducible input 207 
depending on the desired application (Fig. 5b). The bidirectional promoter PR/PRM consists of 208 
three operator sites (O1-O2-O3) where λ cI binding to O1-O2 leads to PRM activation41. 209 
Counterselection via repression is achieved by putting a specific DNA sequence at operator 210 
position O3 which is located between the -35 and -10 regions. For example, the O3 site of 211 
the PRM promoter can be replaced with the consensus wild-type (WT) sequence called OCS. 212 
Thus, binding of a cIopt library member to O1-O2 of an engineered PM promoter activates 213 
gene VI expression (and so promotes selection) while simultaneous binding to WT O3 214 
represses gene VI, enabling counterselection against unwanted WT activity. Positive and 215 
negative selections against the synthetic promoters PM,5G6G and PM,5T6T are depicted as 216 
examples for this protocol (Supplementary Fig. 1). The engineered promoters are 217 
designated according to the positions of the base substitutions in the consensus half-site of 218 
O1 and O2. 219 
Reporter plasmid (RP) design. This protocol describes the downstream functional 220 
characterization of evolved TFs by fluorescence analysis. It has to be noted that a suitable 221 
reporter assay needs to be adapted to the target protein’s properties according to the user’s 222 
needs. To achieve this, the bidirectional PR/PRM promoter on the RP plasmid (pJPC12-ΔPS-223 
mCherry-PR/PRM-GFP) has to be replaced by the same inducible input used on the AP for 224 
selection (Fig. 5c). The insertion of the bidirectional promoters P/PM,5G6G and P/PM,5T6T into 225 
the RP is depicted as examples for this protocol (Supplementary Fig. 2). For other target 226 
proteins, it might be sufficient to use one of the two reporters to analyse activity of the 227 
selected proteins. 228 
Control selections. Enrichment assays can be performed to test the efficiency of the 229 
selection process. Mix plasmids containing λ cIopt (Addgene plasmid ID: 80852) and one of 230 
the orthogonal cI variants (e.g. cI5G6G,P; Addgene plasmid ID: 80861) in different ratios (e.g. 231 
10-3 and 10-6).  Then transform these into TOP10 cells with the modified helper phage 232 
M13KO7-ΔPS-ΔgeneIII-ΔgeneVI and the accessory plasmid pJPC12-ΔPS-PRM-B0034-233 








23-38). Use the obtained phage population and run a batch selection using the accessory 235 
plasmid pJPC12-ΔPS-PRM-B0034-geneVI (steps 41-61). Enrichment of λ cIopt can be 236 
monitored by infecting TG1 cells (containing the plasmid pJPC12-ΔPS-mCherry-PR/PRM-237 
GFP; Addgene plasmid ID: 80859) with the phage titer obtained after each round of 238 
selection. Streak out infected cells on agar plates supplemented with chloramphenicol and 239 
ampicillin and grow overnight at 37°C. The next day, analyse plates under the UV light of a 240 
gel documentation system. The ratio of green to red colonies should increase over time 241 
because the non-active TF cI5G6G,P results in red colonies while the enriched active cIopt leads 242 
to green colonies due to GFP activation and mCherry repression. As an alternative control 243 
selection, the transcription factor cI5G6G,P can be replaced by a reporter (e.g. a red fluorescent 244 
protein, RFP) on the PM and the selection process can be monitored by infecting TG1 cells 245 




Cloning and plasmid construction 250 
• Plasmids: M13KO7-ΔPS-ΔgeneIII-ΔgeneVI (Addgene plasmid ID: 80840), pLITMUS-251 
rpoN-cIopt-J23106-geneIII (Addgene plasmid ID: 80852), pJPC12-ΔPS-PRM-B0034-geneVI 252 
(Addgene plasmid ID: 80858), optional: pJPC12-ΔPS-mCherry-PR/PRM-GFP (Addgene 253 
plasmid ID: 80859), pLITMUS-rpoN-cI5G6G,P-J23106-geneIII (Addgene plasmid ID: 80861) 254 
(Supplementary Fig. 3, Supplementary Table 1). Sequences of all plasmids are listed in 255 
Supplementary Data 1-5. 256 
• Oligonucleotides (Sigma). Primers used for cloning are listed in Supplementary Table 2. 257 
• KOD Hot Start DNA Polymerase (Merck Millipore, cat. no. 71086). PCR reaction 258 
components are listed in the Equipment Setup. 259 
• Diethyl pyrocarbonate (DEPC)-treated and sterile filtered water (Sigma, cat. no. 95284) 260 
• Gibson Assembly Master Mix (New England BioLabs, cat. no. E2611) 261 
• DpnI endonuclease (New England BioLabs, cat. no. R0176) 262 
• Super Optimal broth with Catabolite repression (S.O.C.) medium (Sigma, cat. no. 263 
15544034) 264 
• DNA Gel Loading Dye, 6× (Thermo Scientific, cat. no. R0611) 265 
• 1 kb Plus DNA Ladder (Thermo Scientific, cat. no. 10787026) 266 
• SYBR Safe DNA Gel Stain (Life Technologies, cat. no. S33102) 267 
• Tris-borate-ethylenediaminetetraacetic acid (TBE) Buffer, 10× (Sigma, cat. no. T4415) 268 








• QIAquick Gel Extraction Kit (Qiagen, cat. no. 28704) 270 
• QIAquick PCR Purification Kit (Qiagen, cat. no. 28104) 271 
• MinElute PCR Purification Kit (Qiagen, cat. no. 28004) 272 
• QIAprep Spin Miniprep Kit (Qiagen, cat. no. 27104) 273 
• HiSpeed Plasmid Maxi Kit (Qiagen, cat. no. 12663) 274 
 275 
Strains, buffers and media 276 
• One Shot Chemically Competent TOP10 E. coli (Fisher Scientific, cat. no. C404010) 277 
• Mix & Go Competent Cells - Strain TG1 (Zymo Research, cat. no. T3017) 278 
• 5-alpha Electrocompetent E. coli, optional (New England BioLabs, cat. no. C2989K) 279 
• Lysogeny broth (LB) with agar (Sigma, cat. no. L2897) 280 
• Ampicillin (Sigma, cat. no. A0166), chloramphenicol (Sigma, cat. no. C0378), kanamycin 281 
(Sigma, cat. no. K4000), carbenicillin disodium salt (Sigma, cat. no. C1389) 282 
• 2× tryptone yeast extract (2×TY): NaCl (Sigma, cat. no. S9888), yeast extract (Sigma, cat. 283 
no. Y1625), tryptone (Sigma, cat. no. T7293) 284 
• Glycerol (Sigma, cat. no. G5516) 285 
• Ethanol (≥ 99.8%) for molecular biology (Merck Millipore, cat. no. 1085430250) 286 
• M9 Minimal Salts, 5× (Sigma, cat. no. M6030) 287 
• M9 plates: bacteriological agar (Sigma, cat. no. A5306), MgSO4 (Sigma, cat. no. M7506), 288 
D-(+)-glucose (Sigma, cat. no. G8270), CaCl2 (Sigma, cat. no. C1016), thiamine-HCl 289 
(Sigma, cat. no. T1270) 290 
 291 
EQUIPMENT 292 
• Polymerase chain reaction (PCR) tubes (VWR, cat. no. 732-0545) 293 
• Microcentrifuge tubes (1.5 ml; Thermo Scientific, cat. no. 05-408-129) 294 
• Conical centrifuge tube, polypropylene, 15 ml (BD Falcon, cat. no. 352097) 295 
• Conical centrifuge tubes, polypropylene, 50 ml (Corning, cat. no. 430829) 296 
• Schott culture flasks, 250 ml (Sigma, cat. no. Z620033) 297 
• Nunc CryoTubes (Thermo Scientific, cat. no. 366656) 298 
• Serological pipettes (5 ml, 10 ml, and 25 ml; Fisher Scientific, cat. nos. 13-678-11D, 13-299 
678-11E and 13-678-11) 300 
• Sterile filters (0.22 µm pore size, Millex-GV, cat. no. SLGV033RS) 301 
• L-shaped cell spreaders (Fisher Scientific, cat. no. 14-665-231) 302 
• Cell culture centrifuge Avanti J-26XP (Beckman Coulter, cat. no. 393124) 303 








• Dri-block heater (Techne, DB100/2) 305 
• Eppendorf Thermomixer Compact (Sigma, cat. no. T1317) 306 
• Balance Sartorius Excellence (Sartorius) 307 
• NanoDrop Lite Spectrophotometer (Thermo Scientific) 308 
• Biophotometer (Eppendorf) 309 
• Biophotometer cuvettes (Sigma, cat. no. Z605050) 310 
• Horizontal gel electrophoresis systems (Bio-Rad) 311 
• Gel documentation system (InGenius 3, Syngene) 312 
• Gene Pulser Cuvette, 0.1 cm electrode (Bio-Rad, cat. no. 165-2089) 313 
• Gene Pulser Xcell Microbial System (Bio-Rad, cat. no. 1652662) 314 
• PCR thermocycler (Bio-Rad S1000, cat. no. 1852196) 315 
• Petri dishes, 57 cm2 (Sigma, cat. no. P7741) 316 
• Mini Incubator (Labnet International, I5110A) 317 
• Nunc Square BioAssay Dishes, 24.1 cm × 24.1 cm (Thermo Scientific, cat. no. 10570502) 318 
• Shaking Incubator SI500 (Stuart) 319 
• Cell culture microplate, 96 well, optional (Greiner Bio-One, cat. no. 655090) 320 
• Infinite M200 plate reader, optional (Tecan) 321 
• Research pipettes: 10 µl, 100 µl, 1000 µl (Sigma, cat. no. Z683884) 322 
• Tips: 10 µl, 200 µl, 1000 µl (Starlab, cat. nos. S1111-3700-C, S1113-1700-C, S1111-323 
6701-C) 324 
 325 
REAGENT SETUP 326 
Antibiotic stocks Prepare 100 mg ml-1 ampicillin in H2O (sterile filtered), 100 mg ml-1 327 
kanamycin in H2O (sterile filtered) and 100 mg ml-1 chloramphenicol in ethanol. Aliquot stocks 328 
into sterile 1.5 ml tubes and store at -20°C for up to 6 months. The final concentrations, if not 329 
stated otherwise, are 100 µg ml-1 ampicillin (1:1000), 50 µg ml-1 kanamycin (1:2000), and 330 
25 µg ml-1 chloramphenicol (1:4000). 331 
Glycerol Prepare a sterile 10% (v/v) glycerol solution in H2O for making electrocompetent 332 
cells. Glycerol stocks are obtained by preparing a sterile 50% (v/v) glycerol solution in H2O 333 
and adding glycerol to the cell culture (f.c. 20% (v/v)) prior to freezing at -80°C. Store glycerol 334 
stock at 4°C for up to 3 months. 335 
TBE electrophoresis buffer Dilute TBE buffer in distilled water to a 1× working solution and 336 








Culture medium Autoclave 2×TY medium (5 g l-1 NaCl, 10 g l-1 yeast extract, 16 g l-1 338 
tryptone) and add antibiotics where appropriate before use. Store medium at 4°C for up to 339 
several months. 340 
LB plates Add 35 g LB powder in 1 l water and autoclave. Add antibiotics where appropriate, 341 
pour into petri dishes and allow to solidify. Store plates at 4°C for up to several weeks. Note 342 
that antibiotics degrade over time which might affect the concentration when stored for 343 
prolonged times. 344 
M9 minimal medium plates Autoclave 7 g bacteriological agar in 500 ml 1x M9 medium. 345 
Add 1 ml 1M MgSO4 (autoclaved), 5 ml 20% (w/v) D-(+)-glucose (sterile filtered), 50 µl 1M 346 
CaCl2 (autoclaved) and 500 µl 1M thiamine-HCl (sterile filtered) to M9 agar just before use. 347 
Add antibiotics where appropriate. Store plates at 4°C for up to several months. 348 
 349 
EQUIPMENT SETUP 350 
PCR thermocycler The PCR reaction components are listed below. 351 
Component Volume [µl] Final concentration 
10× Buffer 5 1× 
25 mM MgSO4 3 1.5 mM 
dNTPs (2 mM each) 5 0.2 mM (each) 
H2O varies 
 
Forward primer (5 µM) 3 0.3 µM 
Reverse primer (5 µM) 3 0.3 µM 
Template DNA varies 0.02-0.2 ng/µl 
KOD DNA Polymerase (1 Unit/µl) 1 0.02 U/µl 
Total reaction volume 50   
CRITICAL: For targets greater than 2 kb, final Mg2+ concentrations are adjusted to 2mM. 352 
 353 
The following conditions are used for all PCR reactions: 354 
Step Conditions 
1. Polymerase activation 95°C, 2 min 
2. Denature 95°C, 30 s 
3. Annealing temperature varies, 30 s 
4. Extension 70°C, time varies 
Repeat steps 2.-4.  Number of cycles vary 
Final extension 70°C, 10 min 
Infinite hold 4°C 
 355 








Infinite M200 plate reader Temperature: 37°C, duration: 10 h, shaking: 281 r.p.m., 357 
absorbance: 600 nm +/- 9 nm, fluorescence mCherry: excitation 585 nm +/- 9 nm; emission 358 
625 nm +/- 20 nm; gain value 70, fluorescence GFP: excitation 485 nm +/- 9 nm; emission 359 
520 nm +/- 20 nm; gain value 40. 360 
 361 
PROCEDURE 362 
Phagemid construction by Gibson Assembly   TIMING 2 weeks 363 
1. Design and order generic forward and reverse primers (e.g. pLITMUS-F and pLITMUS-364 
R; Supplementary Table 2) for the amplification of the PM vector backbone (pLITMUS-365 
rpoN-cIopt-J23106-geneIII) upstream of cIopt and downstream the terminator BBa_B0015. 366 
Note that the terminator BBa_B0015 occurs twice in the parental plasmid. The "medium 367 
strength" rpoN promoter is used to express the evolving gene to achieve a balance 368 
between functional expression and any potential metabolic load. The levels of the 369 
expressed target gene may need to be adjusted to the function in other cases. 370 
2. Design and order user-specific primers (e.g. cI-F and cI-R; Supplementary Table 2) for 371 
the gene of interest plus terminator of choice (e.g. BBa_B0015) with a 15-25 bp overlap 372 
to the PM vector backbone. 373 
3. Amplify the gene of interest and vector backbone by PCR (See Equipment Setup) and 374 
purify the samples using the QIAquick PCR Purification Kit. pCRITICAL STEP If the 375 
PCR reactions contain unwanted by-products, gel extraction should be performed 376 
throughout the protocol using the QIAquick Gel Extraction Kit. Use a DNA polymerase 377 
with proof-reading activity (e.g. KOD DNA Polymerase) for all PCR reactions throughout 378 
the protocol. 379 
4. Remove the parental plasmid by adding 1 µl DpnI per 50 µl PCR reaction product and 380 
incubating for 1-2 h at 37°C and 400 r.p.m. (Thermomixer Compact). 381 
5. Fuse the two fragments by Gibson Assembly38 according to the manufacturer’s 382 
instructions. Note that Gibson reactions can be downscaled to 5 µl per reaction. 383 
6. Dilute the assembled products 4-fold with H2O, add 2 µl of the diluted product to 50 µl 384 
chemically competent Top10 cells and transform the cells according to the 385 
manufacturer’s instructions. 386 
7. Incubate the cells for 1 h at 37°C, 220 r.p.m. (incubator SI500) and spread them onto LB 387 
plates supplemented with 100 µg ml-1 ampicillin. 388 
8. Grow the cells overnight at 37°C. 389 
9. The next day, pick single colonies and grow them in 5 ml 2×TY supplemented with 390 








10. Extract the phagemid DNA (QIAprep Spin Miniprep Kit) according to the manufacturer’s 392 
instructions and confirm the nucleotide sequences by DNA sequencing using the primers 393 
pLITMUS-F and pLITMUS-R (Table 1). 394 
 395 
Combinatorial library cloning on phagemids   TIMING 2 weeks 396 
11. Design and order user-specific forward and reverse primers for the amplification of the 397 
PM vector backbone (e.g. pLITMUS-Lib-F and pLITMUS-Lib-R; Supplementary Table 398 
2) and the insertion of the randomized target sequence (e.g. Library 1-F, Library 1-R; 399 
Supplementary Table 2). PCR primers for insert amplification require a 15-25 bp 400 
overlap with each other as well as a 15-25 bp overlap with the amplified vector 401 
backbone. pCRITICAL STEP Avoid randomized library positions within the primer 402 
overlap regions. 403 
12. Amplify the PCR fragments (see Equipment Setup) and purify the samples using the 404 
QIAquick PCR Purification Kit or the MinElute PCR Purification Kit (for samples 405 
<100 bp). pCRITICAL STEP The PCR product concentration affects the efficiency of 406 
the assembly reaction. Optimized cloning efficiency requires at least 20 ng µl-1 of the PM 407 
vector backbone. 408 
13. Add 1 µl DpnI per 50 µl PCR reaction product and incubate for 1-2 h at 37°C and 409 
400 r.p.m. (Thermomixer Compact). 410 
14. Fuse the DNA fragments by Gibson Assembly38. Upscale Gibson reactions (e.g. 4 × 411 
20 µl) to increase the total plasmid concentration. 412 
15. Pool the Gibson reactions, purify the assembled plasmid using the QIAquick PCR 413 
Purification Kit and elute in 30 µl H2O. pCRITICAL STEP Note that purification is 414 
important to decrease the salt concentration and to decrease the Gibson reaction 415 
components as these are toxic to the cells at high concentrations. 416 
16. Measure the plasmid concentration with a spectrophotometer (NanoDrop Lite). 417 
pCRITICAL STEP DNA concentrations should be >10 ng µl-1 for high transformation 418 
efficiency. 419 
17. Transform 1-2 µl of DNA into 50 µl electrocompetent cells (DH5-alpha or TG1) and add 420 
950 µl S.O.C medium. pCRITICAL STEP Use electroporation as the method of choice 421 
for transformation as it allows much larger library sizes. 422 
18. Incubate for 1 h at 37°C, 220 r.p.m. (incubator SI500). 423 
19. Plate the transformation reaction on Nunc Square BioAssay Dishes (24.1 cm × 24.1 cm) 424 
supplemented with 100 µg ml-1 ampicillin and incubate overnight at 37°C. 425 
20. The next day, harvest the cells with a cell spreader. pCRITICAL STEP Only use plates 426 








serial dilutions (10-2 and 10-4 in 2×TY) on additional petri dishes (57 cm2) supplemented 428 
with 100 µg ml-1 ampicillin and colony counting the following day. Ideally, to cover the 429 
whole library space, at least a 3-fold excess of colonies relative to the theoretical library 430 
size is desired. ? TROUBLESHOOTING 431 
21. Purify the combinatorial DNA library using the HiSpeed Plasmid Maxi Kit and elute in 432 
0.5 ml TE buffer. Measure the plasmid concentration with a spectrophotometer 433 
(NanoDrop Lite). The obtained plasmid concentration should ideally be >50 ng ml-1. 434 
22. Pick individual colonies (10-100 clones of a library depending on the library size and 435 
quality control desired) from the petri dishes which were used to estimate the 436 
transformation efficiency (see Step 20) and culture each in 5 ml 2×TY supplemented 437 
with 100 µg ml-1 ampicillin overnight at 37°C, 220 r.p.m. (incubator SI500). The next day, 438 
extract phagemid DNA (QIAprep Spin Miniprep Kit) and sequence the gene of interest 439 
using the primers pLITMUS-F and/or pLITMUS-R to confirm library diversity (Table 1). 440 
? TROUBLESHOOTING 441 
 442 
Production of M13 phage from a combinatorial phagemid library   TIMING 1 week 443 
23. Transform 50 µl chemically competent Top10 cells with equal moles of HP (M13KO7-444 
ΔPS-ΔgeneIII-ΔgeneVI) and AP (pJPC12-ΔPS-PRM-B0034-geneVI) (10-20 fmol per 445 
plasmid, typically 1-2 µl in total). Note that the PRM promoter can be replaced by an 446 
alternative promoter (e.g. T7) to obtain higher phage titers in the absence of the activator 447 
λ cI. 448 
24. Add 250 µl S.O.C. medium to the samples and incubate for 1 h at 37°C, 220 r.p.m. 449 
(incubator SI500). 450 
25. Spread the cells on LB plates supplemented with 25 µg ml-1 chloramphenicol and 50 µg 451 
ml-1 kanamycin. Grow overnight at 37°C. 452 
26. The next day, pick a single colony, grow in 2×TY supplemented with 12.5 µg ml-1 453 
chloramphenicol and 25 µg ml-1 kanamycin at 37°C, 250 r.p.m. (incubator SI500) until 454 
the OD600 reaches 0.4-0.6 (mid-exponential phase) and make cells electrocompetent as 455 
described in Gonzales et al.42. 456 
n PAUSE POINT Stored electrocompetent cells can be used for the construction of any 457 
phage library. 458 
27. Transfer 50 µl of the electrocompetent cells to a prechilled 1.5 ml tube on ice and add 1-459 
2 µl of the cloned combinatorial phagemid library. 460 
28. Electroporate cells, add immediately 950 µl S.O.C. medium and incubate for 1 h at 37°C, 461 








29. Estimate the actual phage library by colony counting of serial dilutions (10-2 and 10-4 in 463 
2×TY) on LB plates supplemented with ampicillin (see step 20). pCRITICAL STEP 464 
Make sure not to lose any library members through low transformation efficiencies. 465 
? TROUBLESHOOTING 466 
30. Add 3 ml 2×TY supplemented with 12.5 µg ml-1 chloramphenicol, 25 µg ml-1 kanamycin, 467 
and 50 µg ml-1 ampicillin to the transformation reaction and grow for 18-20 h at 30°C, 468 
250 r.p.m. (incubator SI500). Note that the volume can be adjusted depending on the 469 
desired volume of the phage titer. 470 
31. The next day, centrifuge sample for 5 min at 5,000 g. 471 
32. Sterile-filter the phage supernatant (0.22 µm pore size). n PAUSE POINT The phage 472 
library can be kept at 4°C for short-term storage (weeks) or at -20°C for the long-term 473 
(years). 474 
 475 
Phage titer analysis   TIMING 3 d 476 
33. Streak out TG1 cells from a glycerol stock (~1-5 µl) on an M9 minimal medium plate and 477 
incubate overnight at 37°C. Note that TG1 plates can be used for a minimum of two 478 
weeks when stored at 4°C. pCRITICAL STEP Use M9 minimal medium plates to select 479 
F-pilus positive TG1 cells. 480 
34. The next day, pick 1-4 single isolated colonies from the M9 minimal medium plate and 481 
inoculate in 10 ml 2×TY medium in a 50 ml conical centrifuge tube. 482 
35. Incubate at 37°C and 250 r.p.m. (incubator SI500) until the OD600 reaches 0.4-0.6 (mid-483 
exponential phase). It typically takes 4-6 hours for the culture to reach the desired OD600. 484 
pCRITICAL STEP Do not let the cells grow into stationary phase as TG1 cells tend to 485 
lose the F’ episome and this lowers the overall infection rate. 486 
36. In the meantime, prepare serial dilutions (10-2, 10-4, 10-6, 10-8 in 2×TY) of the phage 487 
library in sterile 1.5 ml tubes. Phage stocks are diluted before infection to ensure that 488 
each cell is only infected by one phage particle (number of colonies on plates equal 489 
number of phage particles). 490 
37. Add 100 µl of the phage dilutions to 900 µl TG1 cells in a sterile microcentrifuge tube. 491 
Mix gently and incubate the samples for 1 h at 37°C with no shaking. Plate 100 µl cell 492 
suspension on prewarmed LB plates supplemented with 100 µg ml-1 ampicillin and 493 
incubate overnight at 37°C. 494 
38. The next day, count the number of colonies and calculate the phage titer (Equation 1). 495 
Ideally, use the plates containing 20 to 400 colonies. Note that the 100-fold dilution 496 
(step 37) has to be taken into consideration. 497 








pCRITICAL STEP The phage titer should lie between 108-1013 colony-forming units (cfu) 499 
per ml. 500 
 501 
Construction of accessory and reporter plasmids   TIMING 2 weeks 502 
39. Order user-specific forward and reverse primers to replace the PRM promoter on the AP 503 
plasmid (pJPC12-ΔPS-PRM-B0034-geneVI) with a different promoter or inducible input. 504 
For vector amplification, use primers B0034-gVI-F and gVI-R that bind upstream and 505 
downstream of PRM (Supplementary Table 2). For insert amplification make sure to add 506 
a 15-25 bp overlap for assembly. Optional: Clone the same inducible input into pJPC12-507 
ΔPS-mCherry-PR/PRM-GFP to obtain a reporter for the functional characterization of 508 
selected proteins. Use primers GFP-F and mCherry-R for vector amplification 509 
(Supplementary Table 2). 510 
40. Clone the accessory and reporter plasmids as described in steps 3-10. Use sequencing 511 
primers pJPC12-F and/or pJPC12-R for gene VI constructs and pJPC12-F2 for reporters 512 
(Table 1). 513 
 514 
Preparation of host cells for directed evolution   TIMING 3 d 515 
41. Transform 50 µl competent TG1 cells with equal moles of HP M13KO7-ΔPS-ΔgeneIII-516 
ΔgeneVI and the cloned accessory plasmid (AP) (10-20 fmol per plasmid, typically 1-2 µl 517 
in total). pCRITICAL STEP Always use an E. coli strain that contains the F-factor 518 
needed for M13 phage infection. 519 
42. Add 250 µl S.O.C. medium to the sample and incubate for 1 h at 37°C, 220 r.p.m. 520 
(incubator SI500). 521 
43. Spread the cells on LB plates supplemented with 25 µg ml-1 chloramphenicol and 50 µg 522 
ml-1 kanamycin and grow cells overnight at 37°C. 523 
44. The next day, pick a single colony and grow cells in 2 ml 2×TY supplemented with 524 
kanamycin and chloramphenicol for 4-6 h at 37°C, 250 r.p.m. (incubator SI500) until the 525 
cells reach the late-exponential phase. 526 
45. (Optional) Make glycerol stock and store at -80°C (see Reagent Setup). 527 
46. Make serial dilutions of the cell suspension (e.g. 10-6 or 10-8 in M9 medium) and spread 528 
the diluted cells on an M9 minimal medium plate supplemented with 25 µg ml-1 529 
chloramphenicol and 50 µg ml-1 kanamycin. These conditions promote phage 530 
infectability by maintaining F’ pili. 531 
47. Incubate plates for 30-48 h at 37°C. Note that bacteria grow much slower on minimal 532 
media than on rich media. This plate is used as a source of fresh colonies for selection 533 








Phage-assisted batch selection   TIMING 2 weeks 535 
48. Inoculate 10-20 ml 2×TY containing 12.5 µg ml-1 chloramphenicol and 12.5 µg ml-1 536 
kanamycin with 1-4 colonies from prepared M9 plate (step 47) in a 50 ml tube (Fig. 6). 537 
49. Grow the starter culture for 6-8 h at 37°C and 250 r.p.m. (incubator SI500) until the 538 
OD600 reaches 0.4-0.6. 539 
50. Infect 10 ml of the starter culture with the combinatorial phage library at a multiplicity of 540 
infection (MOI) of 0.5-5. An excess of cell culture can be chilled on ice and then be 541 
stored at 4°C for up to one week. This culture may be used for the next rounds of 542 
selection. Note that the selection volume can be easily up- or downscaled according to 543 
the user’s need. 544 
51. Incubate the infected cells at 37°C without stirring for 5 min. 545 
52. Incubate the sample for 18-20 h at 30°C and 250 r.p.m. (incubator SI500). 546 
53. The next day, centrifuge the culture for 5 min at 5,000 g and transfer 1 ml of the 547 
supernatant into a sterile microfuge tube. This sample is used to start a new round of 548 
selection.  549 
n PAUSE POINT Phage supernatants for each round of selection can be stored at 4°C 550 
for short-term storage, or at -20°C for the long-term, to continue selection at a later time. 551 
54. Infect the starter culture (step 49) at a ratio of 10-3-10-1 (e.g. 10-1000 µl phage 552 
supernatant in 10 ml culture) for the next round of selection. 553 
55. Run selection cycle (steps 51-54) for several rounds until the target protein(s) are 554 
enriched. This usually takes four to eight rounds depending on the target protein’s 555 
activity and thus the conditional gene VI expression. pCRITICAL STEP The phage titer 556 
should ideally stay between 106-1012 cfu ml-1 after each round of the selection (see 557 
step 56). Very high infection rates (MOI >10) lead to multiple infections and thus 558 
propagation of non-functional library members (‘cheaters’) whereas very low rates (MOI 559 
<0.1) decrease the performance of the system. ? TROUBLESHOOTING 560 
56. (Optional) During the selection process, monitor the phage titer for each round by phage 561 
titer analysis (steps 33-38). ? TROUBLESHOOTING 562 
57. (Optional) Monitor the selection process by infecting reporter cells (TG1 with a suitable 563 
reporter plasmid, e.g. pJPC12-ΔPS-mCherry-P/PM,5G6G-GFP) with the obtained phage 564 
titer for each round (analogous to steps 33-38). Streak out infected cells on LB plates 565 
supplemented with 25 µg ml-1 chloramphenicol and 100 µg ml-1 ampicillin and grow 566 
overnight at 37°C. The next day, analyse the plates under the UV light of a gel 567 
documentation system. Non-active library member result in red colonies while active 568 
library members lead to green colonies due to GFP activation and mCherry repression. 569 








58. After selection, sterile-filter the phage supernatant (0.22 µm pore size) and serial dilute 571 
the sample with 2×TY medium before infecting TG1 cells with an OD600 of 0.4-0.6. 572 
Incubate the infected cells for 1 h at 37°C before plating (see step 37). 573 
59. Select infected cells on 100 µg ml-1 ampicillin plates overnight at 37°C. 574 
60. The next day, pick at least three colonies per selection and grow each colony in 5 ml 575 
2×TY supplemented with ampicillin overnight at 37°C and 250 r.p.m. (incubator SI500). 576 
61. The next day, extract phagemid DNA (QIAprep Spin Miniprep Kit) and sequence the 577 
gene of interest using the primers pLITMUS-F and/or pLITMUS-R (Table 1). 578 
 579 
Characterization of evolved proteins (optional)   TIMING 3 d 580 
62. Transform 50 µl competent TG1 cells with equal moles of a selected phagemid and a 581 
suitable reporter plasmid (e.g. pJPC12-ΔPS-mCherry-P/PM,5G6G-GFP) (10-20 fmol per 582 
plasmid, typically 1-2 µl in total). Transform the reporter plasmid into TG1 cells and use 583 
as a control. (Optional) Delete the expression cassette rpoN-cIopt-B0015 from the 584 
phagemid (e.g. pLITMUS-ΔcIopt-F, pLITMUS-ΔcIopt-R) and transform the obtained 585 
plasmid (pLITMUS-J23106-geneIII) together with the reporter to compensate for growth 586 
effects between control and selected phagemids. 587 
63. Spread the cells on LB plates supplemented with 25 µg ml-1 chloramphenicol and 100 µg 588 
ml-1 ampicillin and grow the cells overnight at 37°C. 589 
64. The next day, pick single colonies and grow in 1 ml 2×TY supplemented with 5 µg ml-1 590 
chloramphenicol and 5 µg ml-1 carbenicillin for 4-6 h at 37°C, 250 r.p.m. (incubator 591 
SI500). Analyse at least three replicates per transformation. 592 
65. Measure OD600 of each replicate (150 µl) using the Tecan Infinite M200 plate reader. 593 
66. Dilute cultures in 2×TY supplemented with 5 µg ml-1 chloramphenicol and 5 µg ml-1 594 
carbenicillin to a final OD600 of 0.01 (150 µl) in a 96-well microplate. 595 
67. Measure the absorbance at 600 nm, green fluorescence (excitation: 485 nm, emission: 596 
520 nm), and red fluorescence (excitation: 585 nm, emission: 625 nm) every 10 min with 597 
the Infinite M200 plate reader (37°C, shaking between readings) until the cells reach 598 
stationary phase. 599 
68. For data analysis use fluorescence readings in the mid-exponential phase (OD600 of 0.2) 600 
and correct absorbance and fluorescence against readings of a TG1 culture. Normalize 601 
the fluorescence for the number of cells by dividing by the absorbance. 602 
 603 
? TROUBLESHOOTING 604 








 TIMING 606 
Phagemid construction by Gibson Assembly 607 
Steps 1-2, design of primers and oligo synthesis by supplier: 1 week 608 
Steps 3-10, cloning of phagemid: 1 week 609 
Combinatorial library cloning on phagemids 610 
Step 11, design of primers and oligo synthesis by supplier: 1 week 611 
Steps 12-22, cloning of combinatorial library: 1 week 612 
Production of M13 phage from a combinatorial phagemid library 613 
Steps 23-32, transfer from plasmid library to phage library: 1 week 614 
Phage titer analysis 615 
Steps 33-38, analysis of phage concentration: 3 d 616 
Construction of accessory and reporter plasmids (can be done in parallel with phage 617 
library cloning) 618 
Step 39, design of primers and oligo synthesis by supplier: 1 week 619 
Step 40, cloning of accessory plasmid and reporter plasmid: 1 week 620 
Preparation of host cells for directed evolution (can be done in parallel after 621 
successful AP cloning) 622 
Steps 41-47, transformation and plating of cells: 3 d 623 
Phage-assisted batch selection 624 
Steps 48-57, batch selections: 1 week 625 
Steps 58-61, extraction and sequencing of selected genes: 1 week 626 
Characterization of evolved proteins (optional) 627 
Steps 62-68, functional characterization by reporter assay: 3 d 628 
 629 
ANTICIPATED RESULTS 630 
The first section of this protocol describes the construction of combinatorial libraries used for 631 
subsequent directed evolution experiments. As examples, we describe the construction of 632 
two cIopt libraries which contain five randomized positions: Library 1 (45S, 46G, 47V, 48G, 633 
55N); Library 2 (45S, 46G, 48G, 49A, 55N). Quality control sequencing of 10-100 clones of a 634 
library may be performed to confirm diversity, depending on the library size and quality 635 
control desired. For example, ten individual clones of a constructed library should ideally 636 
result in ten different variants (Table 3). 637 
 638 
The second section illustrates the directed evolution of proteins based on conditional M13 639 
phage propagation. Libraries 1 and 2 are selected against engineered promoters for six to 640 








promoters (Table 4). We frequently obtain amino acid substitutions that occur spontaneously 642 
at certain positions not covered by the combinatorial space of the library. These mutations 643 
can originate either from mutations during library cloning or from the spontaneous error rate 644 
of M13 phage replication which is ~0.0046 mutation rate per genome per replication43. Such 645 
mutations can provide function1 and contribute towards directed evolution. 646 
 647 
The last section of the protocol describes the characterization of selected TFs. The reporter 648 
assay is designed in a way that TF binding to the bidirectional promoter results in GFP 649 
activation and mCherry repression. For baseline comparison, GFP and mCherry expression 650 
is measured for each promoter in the absence of a TF. The evolved TF variants enable 651 
simultaneous activation and repression against their engineered bidirectional promoters. For 652 
the selected cI variant (cI5G6G,P) against the bidirectional promoter P/PM,5G6G, GFP production 653 
is upregulated 10-fold and 94% of mCherry is repressed (Fig. 7a,b). The evolved cI variant 654 
(cI5T6T,P) against the bidirectional promoter P/PM,5T6T results in a 9-fold activation and 98% 655 
mCherry repression (Fig. 7c,d). This protocol further shows a method to analyse cross-656 
reactivities for DNA-binding proteins. WT cI and cIopt activate GFP 6-fold and 9-fold and 657 
simultaneously repress 90% and 82% of mCherry production on the WT PR/PRM promoter 658 
whereas this effect is not observed for any of the engineered promoter variants (Fig. 7e,f). 659 
The selected TFs also do not cross-react with each other, thus ensuring orthogonality. 660 
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Figure 1. Intracellular directed evolution of proteins from combinatorial libraries based on 788 
conditional phage replication. 1) Phagemid library generation: A combinatorial DNA library is 789 
generated from the target gene on a phagemid (PM), which also contains conditionally expressed M13 790 
gene III and the M13 packaging signal. The DNA library members are then packaged into phage 791 
particles which are the starting point for selection. 2) Selection cycles: TG1 cells containing a modified 792 
helper phage (HP) and an accessory plasmid (AP) are infected with the constructed phage library. The 793 
HP provides all that is required for phage propagation, except for two essential genes (gIII and gVI). 794 
The AP contains a conditional gene circuit that links the target protein’s activity to conditional phage 795 
production (gene VI expression). Enrichment for a particular protein function occurs after several 796 
rounds of selection. 3) Gene isolation: Cells are infected with selected phages and the phagemid DNA 797 
is amplified and purified. 4) Protein characterization: The target protein’s activity needs to be analysed 798 
using a suitable reporter assay. 799 
 800 









Figure 2. Flowchart and timeline of the directed evolution protocol. All major steps for design, 803 
cloning, selection and functional characterization are depicted. It takes ~7 weeks to select a candidate 804 
protein from a constructed combinatorial library. 805 
 806 









Figure 3. Directed evolution of proteins from combinatorial libraries. (a) Plasmids needed to set 809 
up the phagemid-based selection system. The modified helper phage HP (M13KO7-ΔPS-ΔgIII-ΔgVI) 810 
contains the kanamycin resistance gene (KanR) and all phage genes required for phage replication 811 
except the genes III and VI. The weak packaging signal (PS) is removed to prevent helper phage 812 
propagation as a phage. The accessory plasmid AP contains the chloramphenicol resistance gene 813 
(CamR) and a conditional gene VI expression circuit, induced by an active library member on the 814 
phagemid (PM). The PM also provides the ampicillin resistance gene (AmpR), the M13 packaging 815 
signal (PS; to allow DNA packaging in phage) as well as constitutively expressed gene III. (b) Scheme 816 
of the intracellular selection process. An active library member on the packaged PM induces gene VI 817 
expression to complete the phage life cycle, thus enriching this variant over time. 818 
 819 
 820 









Figure 4. Linkage of an evolving protein’s activity to conditional M13 phage propagation. (a) An 823 
evolving transcription factor1 (e.g. λ cI) activates gene VI expression downstream of a specific 824 
promoter (e.g. λ PRM). This example is depicted in this protocol by selecting new activators against 825 
engineered synthetic promoters. (b) An evolving RNA polymerase22 (grey) enables transcription and 826 
hence gene VI expression. (c) An evolving DNA-binding protein (red) derived from genome-editing 827 
systems (transcription activator-like effector nucleases; TALENs)11 is linked to the ω subunit of 828 
bacterial RNA polymerase III (grey). Binding to a target DNA sequence (dark blue) upstream of a 829 
minimal lac promoter (black) induces transcription of gene VI. (d) The target protein (dark blue) is 830 
bound to the DNA upstream the promoter PlacZ-opt (black) via a fused DNA-binding domain (orange) 831 
and the RNA polymerase omega subunit (RpoZ, yellow) is fused to the evolving protein (red). Target 832 
protein binding of the evolving protein24 enables the localization of RNA polymerase upstream gene 833 
VI, initiating gene expression from the PlacZ-opt promoter. (e) The T7 polymerase (grey) is inhibited 834 
when bound to T7 lysozyme (dark blue) as it inhibits transcription initiation and the transition from 835 
initiation to elongation44. Proteolysis of the target cleavage site (red) by an evolving protease23 836 
activates the T7 RNA polymerase enabling gene VI expression downstream of the T7 promoter. 837 
Gene VI is annotated with an asterisk where originally conditional gene III was used instead of gene VI 838 
using PACE11,22-24. Gene III and gene VI are both minor coat proteins, each present in 3-5 copies per 839 
phage particle21. 840 










Figure 5. Experimental design and cloning strategy. (a) Combinatorial library construction on 844 
phagemids (PM). Randomized oligonucleotides require a 15-25 bp overlap with each other as well as 845 
a 15-25 bp overlap with the amplified vector backbone and are fused by PCR. Randomized positions 846 
are marked with an ‘x’ and must be avoided within overlap regions. Primers 3 and 4 bind upstream 847 
and downstream of the randomized target region and are used for vector linearization. (b) Accessory 848 
plasmid (AP) design. The conditional gene circuit that links an inducible input to gVI expression has to 849 
be adapted for individual needs. This is achieved by replacing the λ PRM promoter with a different 850 
promoter or inducible input depending on the desired application. For example, an engineered 851 
promoter (e.g. PM,5G6G) is constructed by overlap extension PCR and inserted into the linearized 852 
fragment by Gibson Assembly. Primers 3 and 4 bind upstream and downstream of λ PRM and are used 853 
to remove the PRM promoter. (c) Reporter plasmid (RP) design. The bidirectional λ PR/PRM is replaced 854 
by the same inducible input used on the AP (e.g. P/PM,5G6G). The fluorescent proteins mCherry and 855 
GFP on the RP are used to characterize the activity of the selected proteins on the PM. Note that the 856 
maximum insert size using overlap extension PCR is limited by oligonucleotide synthesis (currently 857 
about 120 bp). 858 
 859 
 860 









Figure 6. Phage-assisted batch selection. A starter culture from TG1 cells containing the modified 863 
M13 helper phage HP (M13KO7-ΔPS-ΔgIII-ΔgVI) and an accessory plasmid AP is prepared and cells 864 
are grown for 6-8 h at 37°C until the OD600 reaches 0.4-0.6. Starter cells are infected with the 865 
constructed phagemid library to start the first round of selection. Conditional phage production is 866 
performed in a shaking incubator for 16-18 h at 30°C and the resulting phage particles are separated 867 
from the cells by centrifugation. The obtained phage stock is used to start a new round of selection by 868 
infecting a fresh starter culture (= Round 2). After several rounds of reinfection and selection, a TG1 869 
preculture is infected with the obtained phage stock and infected TG1 cells are selected on LB plates 870 
supplemented with ampicillin. Single colonies are picked and cells are grown overnight at 37°C in a 871 
shaking incubator. The next day, phagemid DNA is purified and the gene of interest is sequenced. 872 
 873 









Figure 7. Dual activation and repression of engineered bidirectional λ P/PM promoters by 876 
selected cI variants. The activity of the selected TFs needs to be verified by a reporter assay. (a,b) 877 
Basal promoter strength of the bidirectional promoter P/PM,5G6G and its dual activation and repression 878 
by the selected TF cI5G6G,P. (c,d) Basal promoter strength of the bidirectional promoter P/PM,5T6T and its 879 
dual activation and repression by the selected TF cI5T6T,P. (e,f) Basal promoter strength of PR/PRM and 880 
its activation-repression by WT λ cI and cIopt. Cross-reactivity of TF variants is ruled out by reporter 881 
analysis. Basal mCherry expression varies between promoters due to base pair substitutions next to 882 
the -35 and -10 regions and y-axes are adjusted accordingly. GFP and mCherry expression was 883 
normalized to OD600. Four biological replicates were measured for each sample and each replicate is 884 
represented by one dot. Error bars show 1 standard deviation. 885 









TABLE 1. Oligonucleotides used for sequencing. 888 
Name Oligonucleotide sequence Step 
pLITMUS-F 5' GTC GAT TTT TGT GAT GCT CG 3' 10, 22, 61 
pLITMUS-R 5' GGG TTA TTG TCT CAT GAG CGG ATA C 3' 10, 22, 61 
pJPC12-F 5' AAA CGA CGG CCA GTG AGC 3' 40 
pJPC12-F2 5' AGC CGT ACA TGA ACT GAG 3' 40 
pJPC12-R 5' GAT AAC AAT TTC ACA CAG G 3' 40 
 889 
TABLE 2. Troubleshooting table. 890 
Step Problem Possible reason Solution 
20 The 
transformation 
efficiency is too 
low 
The DNA 
concentration of the 
cloned library too low 
- Harvest and pool several transformation 
reactions to increase the practical library 
size;  
- Optimize the cloning procedure (e.g. PCR 
reactions) to increase library concentration;   
- Check cell competency 
 
22 The library 
contains the 
parental plasmid 
DpnI digestion was 
incomplete 
- Gel extract the PCR-amplified pLITMUS 
vector backbone;  





efficiency is too 
low 
The competency of 
prepared cells is 
insufficient 
- Harvest and pool several transformation 
reactions to increase library size;  
- Optimize the procedure for making 
competent cells (e.g. do not freeze cells 
before transformation) 
 
55 A large number 
of phages is lost 
during selection 
 
The infection rate is 
too low 
- Increase the volume of supernatant for 
infection;  
- Phage enrichment via polyethylene glycol 
(PEG) precipitation is generally not needed 
but can be performed to increase the phage 
titer for the next round of selection 
 




The infection rate is 
too high 
Decrease the volume of supernatant to lower 
the MOI 
56 No enrichment 
of target 
proteins 
The phage library does 
not contain functional 
library members 
- Redesign and reconstruct the combinatorial 
library;  
- Check with a positive WT control diluted in 
non-functional phage (see control selections 
in Experimental design) 
 891 








TABLE 3. Sequencing results of a combinatorial cIopt library. 10 clones are shown for illustration, 893 
below. Typically 10-100 clones of a library (e.g. Library 1: 45S, 46G, 47V, 48G, 55N) may be 894 
sequenced to confirm diversity, depending on the library size and quality control desired. The obtained 895 
base pairs at the randomized NNS motifs were translated into their corresponding amino acids. Wild-896 
type amino acids are highlighted in blue. The library contains five randomized amino acid positions 897 
known to contact promoter DNA45-47. This results in a combinatorial space of 3.2×106 variants. 898 
Position 45 46 47 48 55 
Clone 1 F T E F N 
Clone 2 P A C F R 
Clone 3 F N P V L 
Clone 4 F Y L S M 
Clone 5 G C L C A 
Clone 6 I P M P T 
Clone 7 F N P F N 
Clone 8 S I G L Y 
Clone 9 K I I Y L 
Clone 10 I T S I T 
Wild-type S G V G N 
 899 
 900 
TABLE 4. Sequencing results of selected TFs. Library 1 (45S, 46G, 47V, 48G, 55N) is selected 901 
against PM,5T6T and Library 2 (45S, 46G, 48G, 49A, 55N) against PM,5G6G while counterselecting 902 
against wild-type binding. Wild-type amino acids are highlighted in blue, randomized positions are 903 
underlined and the amino acid that is not part of the combinatorial library is annotated with an asterisk. 904 
Positions 35, 38, 39 illustrate the amino acid mutations in λ cI to obtain cIopt and are denoted by a “P” 905 
for selected variants (e.g. cI5G6G,P). 906 
Position 35 38 39 43 44 45 46 47 48 49 55 
cI S D K G Q S G V G A N 
cIopt L Y E G Q S G V G A N 
cI5G6G,P L Y E G Q S A V S E W 
























        5T6T             5T6T            CS 
Supplementary Figure 1. Sequences of engineered promoters used for phage-assisted 
selections. The natural operator O3 of PR/PRM is replaced by the natural operator OR1 from 
cI434 in pJPC12-ΔPS-PRM-B0034-geneVI (Addgene plasmid ID: 80858) in order to bypass 
autorepression at high cI concentration (mismatches are shown in red). Synthetic promoters 
are derived from the consensus sequence CS (TATCACCGCCGGTGATA) of bacteriophage 
λ operators. Mutated base pairs in O1 and O2 of synthetic promoters are bold and the 
engineered promoters are named after the position of the base substitution in the consensus 
half-site. WT cI binding to O3 was restored for counterselections by inserting the CS at O3. 
For selections, the promoter variants are used as unidirectional promoters with M13 gene VI 
downstream PM variants on the accessory plasmid. Operators are highlighted as follows: O1 
























        5T6T             5T6T           obliterated 
Supplementary Figure 2. Sequences of synthetic promoters used for functional 
characterization of selected TF variants. The natural operator O3 of PR/PRM is replaced by 
an obliterated O3 site1 in order to bypass autorepression at high cI concentration. Synthetic 
promoters are derived from the consensus sequence CS (TATCACCGCCGGTGATA) of 
bacteriophage λ operators. Mutated base pairs in O1 and O2 of synthetic promoters are bold 
and the engineered promoters are named after the position of the base substitution in the 
consensus half-site. For functional characterization of selected TFs, the bidirectional promoter 
variants are used upstream of GFP and mCherry on the reporter plasmid. Operators are 





Supplementary Figure 3. Plasmid maps needed to set up the directed evolution 
system. (a) The modified helper phage HP (M13KO7-ΔPS-ΔgeneIII-ΔgeneVI) contains all 
phage genes required for phage replication except the genes III and VI. The weak packaging 
signal (PS) is removed to bypass helper phage propagation. (b) The phagemid pLITMUS-
rpoN-cIopt-J23106-gIII provides the gene of interest cIopt, the M13 packaging signal (PS) as 
well as constitutively expressed gene III. (c) The accessory plasmid pJPC12-ΔPS-PRM-gVI 
contains a conditional gene VI expression circuit, induced by an active library member on the 
phagemid. (d) The reporter plasmid pJPC12-ΔPS-mCherry-PR/PRM-GFP is used to 
characterize the selected library members. For additional information on the pJPC12 vector 





Supplementary Table 1. Plasmids used in this protocol. A minimal set of four plasmids 
(annotated with an asterisk) is required to set up the entire selection system plus subsequent 
reporter analysis (Supplementary Fig. 3). Sequences and plasmid maps, as well as DNA 
plasmids have been deposited and are available from Addgene (https://www.addgene.org/). 
For a more comprehensive list of deposited plasmids see reference 3. 
Plasmid Class Antibiotic resistance Addgene ID 
M13KO7-ΔPS-ΔgeneIII-ΔgeneVI* HP Kanamycin 80840 
pLITMUS-J23106-geneIII PM Ampicillin   
pLITMUS-rpoN-cI-J23106-geneIII PM Ampicillin 80843 
pLITMUS-rpoN-cIopt-J23106-geneIII* PM Ampicillin 80852 
pLITMUS-rpoN-cI5G6G,P-J23106-geneIII PM Ampicillin 80861 
pLITMUS-rpoN-cI5T6T,P-J23106-geneIII PM Ampicillin   
pJPC12-ΔPS-PRM-B0034-geneVI* AP Chloramphenicol 80858 
pJPC12-ΔPS-PM,5G6G-OCS3-B0034-geneVI AP Chloramphenicol   
pJPC12-ΔPS-PM,5T6T-OCS3-B0034-geneVI AP Chloramphenicol   
pJPC12-ΔPS-mCherry-PR/PRM-GFP* RP Chloramphenicol 80859 
pJPC12-ΔPS-mCherry-P/PM,5G6G-GFP RP Chloramphenicol 80911 





Supplementary Table 2. Primers used for cloning. The complementary sequences used for Gibson Assembly are underlined. Oligonucleotides used for 
combinatorial library cloning obtain NNS codons (where S = G/C) at the randomized positions. 
Name Oligonucleotide sequence Use Step 
pLITMUS-F 5' GGT CTC CTG GCC TGC AGT AAA G 3' PM linearization 1 
pLITMUS-R 5' GTT CAG AAT CGT ACT CTC CTG C 3' PM linearization 1 
cI-F 5' GGA GAG TAC GAT TCT GAA CAT GAG CAC AAA AAA GAA AC 3' Amplification of target gene 2 
cI-R 5' CTT TAC TGC AGG CCA GGA GAC CTA TAA ACG CAG AAA GGC CC 3' Amplification of target gene 2 
pLITMUS-Lib-F 5' GCA TTA AAT GCT TAT AAC GC 3' PM linearization for library construction 11 
pLITMUS-Lib-R 5' CAT CCC CAT CTC GTA TGC 3' PM linearization for library construction 11 
Library 1-F 
5' GTC GCA TAC GAG ATG GGG ATG GGG CAG NNS NNS NNS NNS GCT TTA 
   TTT AAT GGC ATC 3' 
Randomized oligos for library construction 11 
Library 1-R 5' GCG TTA TAA GCA TTT AAT GCS NNG ATG CCA TTA AAT AAA GC 3' Randomized oligos for library construction 11 
Library 2-F 5' GTC GCA TAC GAG ATG GGG ATG GGG CAG NNS NNS GTT NNS NNS TTA    TTT AAT GGC ATC NNS GCA TTA AAT GCT TAT AAC GC 3' 
Randomized oligos for library construction 11 
Library 2-R 5' GCG TTA TAA GCA TTT AAT GC 3' Randomized oligos for library construction 11 
pLITMUS-ΔcIopt-F 5' TTA GAA TTC GCT GAG AGA CCG GTC TCC TGG CCT GCA G 3' Deletion of rpoN-cIopt-B0015 cassette 62 
pLITMUS-ΔcIopt-R 5' CTG CAG GCC AGG AGA CCG GTC TCT CAG CGA ATT CTA A 3' Deletion of rpoN-cIopt-B0015 cassette 62 
B0034-gVI-F 5' AAA GAG GAG AAA TAC TAG ATG CC 3' AP linearization 39 
gVI-R 5' GTT GCG AAT TCG ATA TCA AG 3' AP linearization 39 
PM,5G6G-OCS3-gVI-F 5' CTT GAT ATC GAA TTC GCA ACC ATT ATC GGC GCC GCC GAT AAA ATA 
   GTC AAC GGC GGC GCC GAT AGA TAT TTA TCA CCG GCG GTG ATA G 3' 
Promoter insertion on AP 39 
PM,5T6T-OCS3-gVI-F 5' CTT GAT ATC GAA TTC GCA ACC ATT ATC TTC GCC GAA GAT AAA ATA 
   GTC AAC TTC GGC GAA GAT AGA TAT TTA TCA CCG GCG GTG ATA G 3' 
Promoter insertion on AP 39 
OCS3-gVI-R 5' CAT CTA GTA TTT CTC CTC TTT ACG TTA AAT CTA TCA CCG CCG GTG 
   ATA AAT ATC 3' 
Promoter insertion on AP 39 
GFP-F 5' AAA GAG GAG AAA TAC TAG ATG 3' RP linearization 39 
mCherry-R 5' GTT GCA AAG AGG AGA AAG 3' RP linearization 39 
P/PM,5G6G-GFP-F 5' ATT CTT TCT CCT CTT TGC AAC CAT TAT CGG CGC CGC CGA TAA AAT 
   AGT CAA CGG CGG CGC CGA TAG ATA TTT ATA AAT AGT GGT GAT AG 3' 
Promoter insertion on RP 39 
P/PM,5T6T-GFP-F 5' ATT CTT TCT CCT CTT TGC AAC CAT TAT CTT CGC CGA AGA TAA AAT 
   AGT CAA CTT CGG CGA AGA TAG ATA TTT ATA AAT AGT GGT GAT AG 3' 
Promoter insertion on RP 39 
P/PM-GFP-R 5' CAT CTA GTA TTT CTC CTC TTT ACG TTA AAT CTA TCA CCA CTA TTT 
   ATA AAT ATC 3' 
Promoter insertion on RP 39 
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3 pLITMUS-F, pLITMUS-R 54 2.5 25 
3 cI-F, cI-R 46 1.0 25 
12 pLITMUS-Lib-F, pLITMUS-Lib-R 50 2.5 25 
12 Library 1-F, Library 1-R 45 0.5 20 
39 B0034-gVI-F, gVI-R 48 3.0 25 
39 PM,5G6G-OCS3-gVI-F, OCS3-gVI-R 54 0.5 20 
39 GFP-F, mCherry-R 45 3.0 25 




Supplementary Data 1. Sequence of the modified helper phage (HP) M13KO7-ΔPS-
ΔgeneIII-ΔgeneVI. The total plasmid size is 6,910 bp. The plasmid is available from Addgene 
(ID 80840). 
 
FEATURES             Location/Qualifiers 
     gene            1..831 
                     /label="Gene II" 
     gene            496..831 
                     /label="Gene X" 
     gene            843..1106 
                     /label="Gene V" 
     gene            1108..1209 
                     /label="Gene VII" 
     gene            1206..1304 
                     /label="Gene IX" 
     gene            1301..1522 
                     /label="Gene VIII" 
     gene            1659..2705 
                     /label="Gene I" 
     gene            2379..2705 
                     /label="Gene XI" 
     gene            2683..3963 
                     /label="Gene IV" 
     terminator      4039..4071 
                     /label=BBa_B1002 
     origin          complement(4287..4832) 
                     /label="p15A ori" 
     gene            complement(5382..6197) 
                     /label="Kanamycin resistance" 
     gene            6507..6910 
                     /label="Gene II" 
 
        1 AACGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAT 
       61 ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT 
      121 CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA 
      181 GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA 
      241 TCCGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG 
      301 TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG 
      361 TCTTTCGGGC TTCCTCTTAA TCTTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT 
      421 CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA 
      481 TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT 
      541 AAACATTTTA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT 
      601 GGTTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT 
      661 AATTCCTTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG 
      721 ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT 
      781 TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA 
      841 CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTT 
      901 CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG 
      961 AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC 
     1021 TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC 
     1081 GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCGA CACAATTTAT 
     1141 CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT 
     1201 CAAAGATGAG TGTTTTAGTG TATTCTTTCG CCTCTTTCGT TTTAGGTTGG TGCCTTCGTA 
     1261 GTGGCATTAC GTATTTTACC CGTTTAATGG AAACTTCCTC ATGAAAAAGT CTTTAGCCCT 
     1321 CAAAGCCTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA 
     1381 CGATCCCGCA AAAGCGGCCT TTAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA 
     1441 TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTTAAGAA 
     1501 ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT 
     1561 TTTTTGGAGA TTTTCAACGT GAAAAAATTA TTATTCGCAA TTCCTTTAGT TGTTCCTTTC 
     1621 TATTCTCACT CCGCTGAAAC TGTTGAAGGA TCCTAATCAT GGCTGTTTAT TTTGTAACTG 
     1681 GCAAATTAGG CTCTGGAAAG ACGCTCGTTA GCGTTGGTAA GATTCAGGAT AAAATTGTAG 
     1741 CTGGGTGCAA AATAGCAACT AATCTTGATT TAAGGCTTCA AAACCTCCCG CAAGTCGGGA 
     1801 GGTTCGCTAA AACGCCTCGC GTTCTTAGAA TACCGGATAA GCCTTCTATA TCTGATTTGC 
     1861 TTGCTATTGG GCGCGGTAAT GATTCCTACG ATGAAAATAA AAACGGCTTG CTTGTTCTCG 
     1921 ATGAGTGCGG TACTTGGTTT AATACCCGTT CTTGGAATGA TAAGGAAAGA CAGCCGATTA 
     1981 TTGATTGGTT TCTACATGCT CGTAAATTAG GATGGGATAT TATTTTTCTT GTTCAGGACT 
     2041 TATCTATTGT TGATAAACAG GCGCGTTCTG CATTAGCTGA ACATGTTGTT TATTGTCGTC 
     2101 GTCTGGACAG AATTACTTTA CCTTTTGTCG GTACTTTATA TTCTCTTATT ACTGGCTCGA 
     2161 AAATGCCTCT GCCTAAATTA CATGTTGGCG TTGTTAAATA TGGCGATTCT CAATTAAGCC 
     2221 CTACTGTTGA GCGTTGGCTT TATACTGGTA AGAATTTGTA TAACGCATAT GATACTAAAC 
     2281 AGGCTTTTTC TAGTAATTAT GATTCCGGTG TTTATTCTTA TTTAACGCCT TATTTATCAC 
     2341 ACGGTCGGTA TTTCAAACCA TTAAATTTAG GTCAGAAGAT GAAATTAACT AAAATATATT 
     2401 TGAAAAAGTT TTCTCGCGTT CTTTGTCTTG CGATTGGATT TGCATCAGCA TTTACATATA 
     2461 GTTATATAAC CCAACCTAAG CCGGAGGTTA AAAAGGTAGT CTCTCAGACC TATGATTTTG 
     2521 ATAAATTCAC TATTGACTCT TCTCAGCGTC TTAATCTAAG CTATCGCTAT GTTTTCAAGG 
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     2581 ATTCTAAGGG AAAATTAATT AATAGCGACG ATTTACAGAA GCAAGGTTAT TCACTCACAT 
     2641 ATATTGATTT ATGTACTGTT TCCATTAAAA AAGGTAATTC AAATGAAATT GTTAAATGTA 
     2701 ATTAATTTTG TTTTCTTGAT GTTTGTTTCA TCATCTTCTT TTGCTCAGGT AATTGAAATG 
     2761 AATAATTCGC CTCTGCGCGA TTTTGTAACT TGGTATTCAA AGCAATCAGG CGAATCCGTT 
     2821 ATTGTTTCTC CCGATGTAAA AGGTACTGTT ACTGTATATT CATCTGACGT TAAACCTGAA 
     2881 AATCTACGCA ATTTCTTTAT TTCTGTTTTA CGTGCAAATA ATTTTGATAT GGTAGGTTCT 
     2941 AACCCTTCCA TTATTCAGAA GTATAATCCA AACAATCAGG ATTATATTGA TGAATTGCCA 
     3001 TCATCTGATA ATCAGGAATA TGATGATAAT TCCGCTCCTT CTGGTGGTTT CTTTGTTCCG 
     3061 CAAAATGATA ATGTTACTCA AACTTTTAAA ATTAATAACG TTCGGGCAAA GGATTTAATA 
     3121 CGAGTTGTCG AATTGTTTGT AAAGTCTAAT ACTTCTAAAT CCTCAAATGT ATTATCTATT 
     3181 GACGGCTCTA ATCTATTAGT TGTTAGTGCT CCTAAAGATA TTTTAGATAA CCTTCCTCAA 
     3241 TTCCTTTCAA CTGTTGATTT GCCAACTGAC CAGATATTGA TTGAGGGTTT GATATTTGAG 
     3301 GTTCAGCAAG GTGATGCTTT AGATTTTTCA TTTGCTGCTG GCTCTCAGCG TGGCACTGTT 
     3361 GCAGGCGGTG TTAATACTGA CCGCCTCACC TCTGTTTTAT CTTCTGCTGG TGGTTCGTTC 
     3421 GGTATTTTTA ATGGCGATGT TTTAGGGCTA TCAGTTCGCG CATTAAAGAC TAATAGCCAT 
     3481 TCAAAAATAT TGTCTGTGCC ACGTATTCTT ACGCTTTCAG GTCAGAAGGG TTCTATCTCT 
     3541 GTTGGCCAGA ATGTCCCTTT TATTACTGGT CGTGTGACTG GTGAATCTGC CAATGTAAAT 
     3601 AATCCATTTC AGACGATTGA GCGTCAAAAT GTAGGTATTT CCATGAGCGT TTTTCCTGTT 
     3661 GCAATGGCTG GCGGTAATAT TGTTCTGGAT ATTACCAGCA AGGCCGATAG TTTGAGTTCT 
     3721 TCTACTCAGG CAAGTGATGT TATTACTAAT CAAAGAAGTA TTGCTACAAC GGTTAATTTG 
     3781 CGTGATGGAC AGACTCTTTT ACTCGGTGGC CTCACTGATT ATAAAAACAC TTCTCAGGAT 
     3841 TCTGGCGTAC CGTTCCTGTC TAAAATCCCT TTAATCGGCC TCCTGTTTAG CTCCCGCTCT 
     3901 GATTCTAACG AGGAAAGCAC GTTATACGTG CTCGTCAAAG CAACCATAGT ACGCGCCCTG 
     3961 TAGCGCAAAA AACCCCGCTT CGGCGGGGTT TTTTCGCACG GATCGCTTCA TGTGGCACCA 
     4021 TAGTACGCGC CCTGTAGCGC AAAAAACCCC GCTTCGGCGG GGTTTTTTCG CACGGATCGC 
     4081 TTCATGTGGC AGGAGAAAAA AGGCTGCACC GGTGCGTCAG CAGAATATGT GATACAGGAT 
     4141 ATATTCCGCT TCCTCGCTCA CTGACTCGCT ACGCTCGGTC GTTCGACTGC GGCGAGCGGA 
     4201 AATGGCTTAC GAACGGGGCG GAGATTTCCT GGAAGATGCC AGGAAGATAC TTAACAGGGA 
     4261 AGTGAGAGGG CCGCGGCAAA GCCGTTTTTC CATAGGCTCC GCCCCCCTGA CAAGCATCAC 
     4321 GAAATCTGAC GCTCAAATCA GTGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG 
     4381 TTTCCCCCTG GCGGCTCCCT CGTGCGCTCT CCTGTTCCTG CCTTTCGGTT TACCGGTGTC 
     4441 ATTCCGCTGT TATGGCCGCG TTTGTCTCAT TCCACGCCTG ACACTCAGTT CCGGGTAGGC 
     4501 AGTTCGCTCC AAGCTGGACT GTATGCACGA ACCCCCCGTT CAGTCCGACC GCTGCGCCTT 
     4561 ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGAAAGACAT GCAAAAGCAC CACTGGCAGC 
     4621 AGCCACTGGT AATTGATTTA GAGGAGTTAG TCTTGAAGTC ATGCGCCGGT TAAGGCTAAA 
     4681 CTGAAAGGAC AAGTTTTGGT GACTGCGCTC CTCCAAGCCA GTTACCTCGG TTCAAAGAGT 
     4741 TGGTAGCTCA GAGAACCTTC GAAAAACCGC CCTGCAAGGC GGTTTTTTCG TTTTCAGAGC 
     4801 AAGAGATTAC GCGCAGACCA AAACGATCTC AAGAAGATCA TCTTATTAAG GGGTCTGACG 
     4861 CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TTTTGGTCAT GAGATTATCA AAAAGGATCT 
     4921 TCACCTAGAT CCTTTTAAAT TAAAAATGAA GTTTTAAATC AATCTAAAGT ATATATGAGT 
     4981 AAACTTGGTC TGACAGTTAC CAATGCTTAA TCAGTGAGGC ACCTATCTCA GCGATCTGTC 
     5041 TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG ATACGGGAGG 
     5101 GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA CCGGCTCCAG 
     5161 ATTTATCAGC AATAAACCAG CCAGCCGATT CGAGCTCGCC CCGGGGATCG ACCAGTTGGT 
     5221 GATTTTGAAC TTTTGCTTTG CCACGGAACG GTCTGCGTTG TCGGGAAGAT GCGTGATCTG 
     5281 ATCCTTCAAC TCAGCAAAAG TTCGATTTAT TCAACAAAGC CGCCGTCCCG TCAAGTCAGC 
     5341 GTAATGCTCT GCCAGTGTTA CAACCAATTA ACCAATTCTG ATTAGAAAAA CTCATCGAGC 
     5401 ATCAAATGAA ACTGCAATTT ATTCATATCA GGATTATCAA TACCATATTT TTGAAAAAGC 
     5461 CGTTTCTGTA ATGAAGGAGA AAACTCACCG AGGCAGTTCC ATAGGATGGC AAGATCCTGG 
     5521 TATCGGTCTG CGATTCCGAC TCGTCCAACA TCAATACAAC CTATTAATTT CCCCTCGTCA 
     5581 AAAATAAGGT TATCAAGTGA GAAATCACCA TGAGTGACGA CTGAATCCGG TGAGAATGGC 
     5641 AAAAGCTTAT GCATTTCTTT CCAGACTTGT TCAACAGGCC AGCCATTACG CTCGTCATCA 
     5701 AAATCACTCG CATCAACCAA ACCGTTATTC ATTCGTGATT GCGCCTGAGC GAGACGAAAT 
     5761 ACGCGATCGC TGTTAAAAGG ACAATTACAA ACAGGAATCG AATGCAACCG GCGCAGGAAC 
     5821 ACTGCCAGCG CATCAACAAT ATTTTCACCT GAATCAGGAT ATTCTTCTAA TACCTGGAAT 
     5881 GCTGTTTTCC CGGGGATCGC AGTGGTGAGT AACCATGCAT CATCAGGAGT ACGGATAAAA 
     5941 TGCTTGATGG TCGGAAGAGG CATAAATTCC GTCAGCCAGT TTAGTCTGAC CATCTCATCT 
     6001 GTAACATCAT TGGCAACGCT ACCTTTGCCA TGTTTCAGAA ACAACTCTGG CGCATCGGGC 
     6061 TTCCCATACA ATCGATAGAT TGTCGCACCT GATTGCCCGA CATTATCGCG AGCCCATTTA 
     6121 TACCCATATA AATCAGCATC CATGTTGGAA TTTAATCGCG GCCTCGAGCA AGACGTTTCC 
     6181 CGTTGAATAT GGCTCATAAC ACCCCTTGTA TTACTGTTTA TGTAAGCAGA CAGTTTTATT 
     6241 GTTCATGATG ATATATTTTT ATCTTGTGCA ATGTAACATC AGAGATTTTG AGACACAACG 
     6301 TGGCTTTCCC CCCCCCCCCC TGCAGGTCTC GGGCTATTCT TTTGATTTAT AAGGGATTTT 
     6361 GCCGATTTCG GCCTATTGGT TAAAAAATGA GCTGATTTAA CAAAAATTTA ACGCGAATTT 
     6421 TAACAAAATA TTAACGTTTA CAATTTAAAT ATTTGCTTAT ACAATCTTCC TGTTTTTGGG 
     6481 GATTTTCTGA TTATCAACCG GGGTACATGT GATTGACATG CTAGTTTTAC GATTACCGTT 
     6541 CATCGATTCT CTTGTTTGCT CCAGACTCTC AGGCAATGAC CTGATAGCCT TTGTAGACCT 
     6601 CTCAAAAATA GCTACCCTCT CCGGCATGAA TTTATCAGCT AGAACGGTTG AATATCATAT 
     6661 TGATGGTGAT TTGACTGTCT CCGGCCTTTC TCACCCTTTT GAATCTTTAC CTACACATTA 
     6721 CTCAGGCATT GCATTTAAAA TATATGAGGG TTCTAAAAAT TTTTATCCTT GCGTTGAAAT 
     6781 AAAGGCTTCT CCCGCAAAAG TATTACAGGG TCATAATGTT TTTGGTACAA CCGATTTAGC 
     6841 TTTATGCTCT GAGGCTTTAT TGCTTAATTT TGCTAATTCT TTGCCTTGCC TGTATGATTT 







Supplementary Data 2. Sequence of the phagemid (PM) pLITMUS-rpoN-cIopt-J23106-
geneIII. Sequencing primers listed in Table 1 are underlined (pLITMUS-F, pLITMUS-R). The 
total plasmid size is 4,924 bp. The plasmid is available from Addgene (ID 80852). 
 
FEATURES             Location/Qualifiers 
     gene            143..1003 
                     /label="Beta-lactamase (Ampicillin resistance)" 
     promoter        1027..1061 
                     /label=BBa_J23106 
     RBS             1068..1079 
                     /label=BBa_B0034 
     gene            1086..2360 
                     /label="Gene III" 
     terminator      2367..2495 
                     /label=BBa_B0015 
     origin          complement(2514..3023) 
                     /label="M13 ori" 
     origin          3134..3722 
                     /label="pMB1 ori" 
     promoter        3824..4012 
                     /label=rpoN 
     gene            4031..4744 
                     /label="lambda cIopt" 
     terminator      4751..4879 
                     /label=BBa_B0015 
 
        1 GTTAACTACG TCAGGTGGCA CTTTTCGGGG AAATGTGCGC GGAACCCCTA TTTGTTTATT 
       61 TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA TAACCCTGAT AAATGCTTCA 
      121 ATAATATTGA AAAAGGAAGA GTATGAGTAT TCAACATTTC CGTGTCGCCC TTATTCCCTT 
      181 TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA ACGCTGGTGA AAGTAAAAGA 
      241 TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA CTGGATCTCA ACAGCGGTAA 
      301 GATCCTTGAG AGTTTTCGCC CCGAAGAACG TTCTCCAATG ATGAGCACTT TTAAAGTTCT 
      361 GCTATGTGGC GCGGTATTAT CCCGTGTTGA CGCCGGGCAA GAGCAACTCG GTCGCCGCAT 
      421 ACACTATTCT CAGAATGACT TGGTTGAGTA CTCACCAGTC ACAGAAAAGC ATCTTACGGA 
      481 TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC ATGAGTGATA ACACTGCGGC 
      541 CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA ACCGCTTTTT TGCACAACAT 
      601 GGGGGATCAT GTAACTCGCC TTGATCGTTG GGAACCGGAG CTGAATGAAG CCATACCAAA 
      661 CGACGAGCGT GACACCACGA TGCCTGTAGC AATGGCAACA ACGTTGCGCA AACTATTAAC 
      721 TGGCGAACTA CTTACTCTAG CTTCCCGGCA ACAATTAATA GACTGGATGG AGGCGGATAA 
      781 AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC TGGTTTATTG CTGATAAATC 
      841 TGGAGCCGGT GAGCGTGGGT CCCGCGGTAT CATTGCAGCA CTGGGGCCAG ATGGTAAGCC 
      901 CTCCCGTATC GTAGTTATCT ACACGACGGG GAGTCAGGCA ACTATGGATG AACGAAATAG 
      961 ACAGATCGCT GAGATAGGTG CCTCACTGAT TAAGCATTGG TAACTGTCAG ACCAAGTTTA 
     1021 CTCATATTTA CGGCTAGCTC AGTCCTAGGT ATAGTGCTAG CGAAGACAAA GAGGAGAAAT 
     1081 ACTAGGTGAA AAAATTATTA TTCGCAATTC CTTTAGTTGT TCCTTTCTAT TCTCACTCCG 
     1141 CTGAAACTGT TGAAAGTTGT TTAGCAAAAT CCCATACAGA AAATTCATTT ACTAACGTCT 
     1201 GGAAAGACGA CAAAACTTTA GATCGTTACG CTAACTATGA GGGCTGTCTG TGGAATGCTA 
     1261 CAGGCGTTGT AGTTTGTACT GGTGACGAAA CTCAGTGTTA CGGTACATGG GTTCCTATTG 
     1321 GGCTTGCTAT CCCTGAAAAT GAGGGTGGTG GCTCTGAGGG TGGCGGTTCT GAGGGTGGCG 
     1381 GTTCTGAGGG TGGCGGTACT AAACCTCCTG AGTACGGTGA TACACCTATT CCGGGCTATA 
     1441 CTTATATCAA CCCTCTCGAC GGCACTTATC CGCCTGGTAC TGAGCAAAAC CCCGCTAATC 
     1501 CTAATCCTTC TCTTGAGGAG TCTCAGCCTC TTAATACTTT CATGTTTCAG AATAATAGGT 
     1561 TCCGAAATAG GCAGGGGGCA TTAACTGTTT ATACGGGCAC TGTTACTCAA GGCACTGACC 
     1621 CCGTTAAAAC TTATTACCAG TACACTCCTG TATCATCAAA AGCCATGTAT GACGCTTACT 
     1681 GGAACGGTAA ATTCAGAGAC TGCGCTTTCC ATTCTGGCTT TAATGAGGAT TTATTTGTTT 
     1741 GTGAATATCA AGGCCAATCG TCTGACCTGC CTCAACCTCC TGTCAATGCT GGCGGCGGCT 
     1801 CTGGTGGTGG TTCTGGTGGC GGCTCTGAGG GTGGTGGCTC TGAGGGTGGC GGTTCTGAGG 
     1861 GTGGCGGCTC TGAGGGAGGC GGTTCCGGTG GTGGCTCTGG TTCCGGTGAT TTTGATTATG 
     1921 AAAAGATGGC AAACGCTAAT AAGGGGGCTA TGACCGAAAA TGCCGATGAA AACGCGCTAC 
     1981 AGTCTGACGC TAAAGGCAAA CTTGATTCTG TCGCTACTGA TTACGGTGCT GCTATCGATG 
     2041 GTTTCATTGG TGACGTTTCC GGCCTTGCTA ATGGTAATGG TGCTACTGGT GATTTTGCTG 
     2101 GCTCTAATTC CCAAATGGCT CAAGTCGGTG ACGGTGATAA TTCACCTTTA ATGAATAATT 
     2161 TCCGTCAATA TTTACCTTCC CTCCCTCAAT CGGTTGAATG TCGCCCTTTT GTCTTTGGCG 
     2221 CTGGTAAACC ATATGAATTT TCTATTGATT GTGACAAAAT AAACTTATTC CGTGGTGTCT 
     2281 TTGCGTTTCT TTTATATGTT GCCACCTTTA TGTATGTATT TTCTACGTTT GCTAACATAC 
     2341 TGCGTAATAA GGAGTCTTAA GAAGACCCAG GCATCAAATA AAACGAAAGG CTCAGTCGAA 
     2401 AGACTGGGCC TTTCGTTTTA TCTGTTGTTT GTCGGTGAAC GCTCTCTACT AGAGTCACAC 
     2461 TGGCTCACCT TCGGGTGGGC CTTTCTGCGT TTATATATAC TTTAGATTGA TTTACCCCGG 
     2521 TTGATAATCA GAAAAGCCCC AAAAACAGGA AGATTGTATA AGCAAATATT TAAATTGTAA 
     2581 ACGTTAATAT TTTGTTAAAA TTCGCGTTAA ATTTTTGTTA AATCAGCTCA TTTTTTAACC 
     2641 AATAGGCCGA AATCGGCAAA ATCCCTTATA AATCAAAAGA ATAGCCCGAG ATAGGGTTGA 
     2701 GTGTTGTTCC AGTTTGGAAC AAGAGTCCAC TATTAAAGAA CGTGGACTCC AACGTCAAAG 
     2761 GGCGAAAAAC CGTCTATCAG GGCGATGGCC CACTACGTGA ACCATCACCC AAATCAAGTT 
     2821 TTTTGGGGTC GAGGTGCCGT AAAGCACTAA ATCGGAACCC TAAAGGGAGC CCCCGATTTA 
     2881 GAGCTTGACG GGGAAAGCGA ACGTGGCGAG AAAGGAAGGG AAGAAAGCGA AAGGAGCGGG 
     2941 CGCTAGGGCG CTGGCAAGTG TAGCGGTCAC GCTGCGCGTA ACCACCACAC CCGCCGCGCT 
Nature Protocols: doi:10.1038/nprot.2017.084
	 10 
     3001 TAATGCGCCG CTACAGGGCG CGTAAAAGGA TCTAGGTGAA GATCCTTTTT GATAATCTCA 
     3061 TGACCAAAAT CCCTTAACGT GAGTTTTCGT TCCACTGAGC GTCAGACCCC GTAGAAAAGA 
     3121 TCAAAGGATC TTCTTGAGAT CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA 
     3181 AACCACCGCT ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA 
     3241 AGGTAACTGG CTTCAGCAGA GCGCAGATAC CAAATACTGT TCTTCTAGTG TAGCCGTAGT 
     3301 TAGGCCACCA CTTCAAGAAC TCTGTAGCAC CGCCTACATA CCTCGCTCTG CTAATCCTGT 
     3361 TACCAGTGGC TGCTGCCAGT GGCGATAAGT CGTGTCTTAC CGGGTTGGAC TCAAGACGAT 
     3421 AGTTACCGGA TAAGGCGCAG CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT 
     3481 TGGAGCGAAC GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCTATGA GAAAGCGCCA 
     3541 CGCTTCCCGA AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG 
     3601 AGCGCACGAG GGAGCTTCCA GGGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC 
     3661 GCCACCTCTG ACTTGAGCGT CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA 
     3721 AAAACGCCAG CAACGCGGCC TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA 
     3781 TGTAATGTGA GTTAGCTCAC TCATTAGAAT TCGCTGAGAG ACCCGTGCTG ATCACTGACC 
     3841 ACAACGTGCG TGAAACACTG GCGGTTTGTG AACGCGCTTA TATCGTCAGT CAGGGGCATT 
     3901 TGATCGCCCA CGGCACGCCT ACAGAAATCT TACAAGACGA ACACGTTAAG CGTGTATACC 
     3961 TTGGGGAAGA CTTCAGACTC TGATAGGGTA GAAGTTTGCG ACGTTTTAGC AGGAGAGTAC 
     4021 GATTCTGAAC ATGAGCACAA AAAAGAAACC ATTAACACAA GAGCAGCTTG AGGACGCACG 
     4081 TCGCCTTAAA GCAATTTATG AAAAAAAGAA AAATGAACTT GGCTTATCCC AGGAATTGGT 
     4141 CGCATACGAG ATGGGGATGG GGCAGTCAGG CGTTGGTGCT TTATTTAATG GCATCAATGC 
     4201 ATTAAATGCT TATAACGCCG CATTGCTTGC AAAAATTCTC AAAGTTAGCG TTGAAGAATT 
     4261 TAGCCCTTCA ATCGCCAGAG AAATCTACGA GATGTATGAA GCGGTTAGTA TGCAGCCGTC 
     4321 ACTTAGAAGT GAGTATGAGT ACCCTGTTTT TTCTCATGTT CAGGCAGGGA TGTTCTCACC 
     4381 TGAGCTTAGA ACCTTTACCA AAGGTGATGC GGAGAGATGG GTAAGCACAA CCAAAAAAGC 
     4441 CAGTGATTCT GCATTCTGGC TTGAGGTTGA AGGTAATTCC ATGACCGCAC CAACAGGCTC 
     4501 CAAGCCAAGC TTTCCTGACG GAATGTTAAT TCTCGTTGAC CCTGAGCAGG CTGTTGAGCC 
     4561 AGGTGATTTC TGCATAGCCA GACTTGGGGG TGATGAGTTT ACCTTCAAGA AACTGATCAG 
     4621 GGATAGCGGT CAGGTGTTTT TACAACCACT AAACCCACAG TACCCAATGA TCCCATGCAA 
     4681 TGAGAGTTGT TCCGTTGTGG GGAAAGTTAT CGCTAGTCAG TGGCCTGAAG AGACGTTTGG 
     4741 CTGAGAAGAC CCAGGCATCA AATAAAACGA AAGGCTCAGT CGAAAGACTG GGCCTTTCGT 
     4801 TTTATCTGTT GTTTGTCGGT GAACGCTCTC TACTAGAGTC ACACTGGCTC ACCTTCGGGT 
     4861 GGGCCTTTCT GCGTTTATAG GTCTCCTGGC CTGCAGTAAA GCCCGCTTCG GCGGGCTTTT 





Supplementary Data 3. Sequence of the phagemid (PM) pLITMUS-rpoN-cI5G6G,P-J23106-
geneIII. Sequencing primers listed in Table 1 are underlined (pLITMUS-F, pLITMUS-R). The 
total plasmid size is 4,924 bp. The plasmid is available from Addgene (ID 80861). 
 
FEATURES             Location/Qualifiers 
     gene            143..1003 
                     /label="Beta-lactamase (Ampicillin resistance)" 
     promoter        1027..1061 
                     /label=BBa_J23106 
     RBS             1068..1079 
                     /label=BBa_B0034 
     gene            1086..2360 
                     /label="Gene III" 
     terminator      2367..2495 
                     /label=BBa_B0015 
     origin          complement(2514..3023) 
                     /label="M13 ori" 
     origin          3134..3722 
                     /label="pMB1 ori" 
     promoter        3824..4012 
                     /label=rpoN 
     gene            4031..4744 
                     /label="cI5G6G,P" 
     terminator      4751..4879 
                     /label=BBa_B0015 
 
        1 GTTAACTACG TCAGGTGGCA CTTTTCGGGG AAATGTGCGC GGAACCCCTA TTTGTTTATT 
       61 TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA TAACCCTGAT AAATGCTTCA 
      121 ATAATATTGA AAAAGGAAGA GTATGAGTAT TCAACATTTC CGTGTCGCCC TTATTCCCTT 
      181 TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA ACGCTGGTGA AAGTAAAAGA 
      241 TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA CTGGATCTCA ACAGCGGTAA 
      301 GATCCTTGAG AGTTTTCGCC CCGAAGAACG TTCTCCAATG ATGAGCACTT TTAAAGTTCT 
      361 GCTATGTGGC GCGGTATTAT CCCGTGTTGA CGCCGGGCAA GAGCAACTCG GTCGCCGCAT 
      421 ACACTATTCT CAGAATGACT TGGTTGAGTA CTCACCAGTC ACAGAAAAGC ATCTTACGGA 
      481 TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC ATGAGTGATA ACACTGCGGC 
      541 CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA ACCGCTTTTT TGCACAACAT 
      601 GGGGGATCAT GTAACTCGCC TTGATCGTTG GGAACCGGAG CTGAATGAAG CCATACCAAA 
      661 CGACGAGCGT GACACCACGA TGCCTGTAGC AATGGCAACA ACGTTGCGCA AACTATTAAC 
      721 TGGCGAACTA CTTACTCTAG CTTCCCGGCA ACAATTAATA GACTGGATGG AGGCGGATAA 
      781 AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC TGGTTTATTG CTGATAAATC 
      841 TGGAGCCGGT GAGCGTGGGT CCCGCGGTAT CATTGCAGCA CTGGGGCCAG ATGGTAAGCC 
      901 CTCCCGTATC GTAGTTATCT ACACGACGGG GAGTCAGGCA ACTATGGATG AACGAAATAG 
      961 ACAGATCGCT GAGATAGGTG CCTCACTGAT TAAGCATTGG TAACTGTCAG ACCAAGTTTA 
     1021 CTCATATTTA CGGCTAGCTC AGTCCTAGGT ATAGTGCTAG CGAAGACAAA GAGGAGAAAT 
     1081 ACTAGGTGAA AAAATTATTA TTCGCAATTC CTTTAGTTGT TCCTTTCTAT TCTCACTCCG 
     1141 CTGAAACTGT TGAAAGTTGT TTAGCAAAAT CCCATACAGA AAATTCATTT ACTAACGTCT 
     1201 GGAAAGACGA CAAAACTTTA GATCGTTACG CTAACTATGA GGGCTGTCTG TGGAATGCTA 
     1261 CAGGCGTTGT AGTTTGTACT GGTGACGAAA CTCAGTGTTA CGGTACATGG GTTCCTATTG 
     1321 GGCTTGCTAT CCCTGAAAAT GAGGGTGGTG GCTCTGAGGG TGGCGGTTCT GAGGGTGGCG 
     1381 GTTCTGAGGG TGGCGGTACT AAACCTCCTG AGTACGGTGA TACACCTATT CCGGGCTATA 
     1441 CTTATATCAA CCCTCTCGAC GGCACTTATC CGCCTGGTAC TGAGCAAAAC CCCGCTAATC 
     1501 CTAATCCTTC TCTTGAGGAG TCTCAGCCTC TTAATACTTT CATGTTTCAG AATAATAGGT 
     1561 TCCGAAATAG GCAGGGGGCA TTAACTGTTT ATACGGGCAC TGTTACTCAA GGCACTGACC 
     1621 CCGTTAAAAC TTATTACCAG TACACTCCTG TATCATCAAA AGCCATGTAT GACGCTTACT 
     1681 GGAACGGTAA ATTCAGAGAC TGCGCTTTCC ATTCTGGCTT TAATGAGGAT TTATTTGTTT 
     1741 GTGAATATCA AGGCCAATCG TCTGACCTGC CTCAACCTCC TGTCAATGCT GGCGGCGGCT 
     1801 CTGGTGGTGG TTCTGGTGGC GGCTCTGAGG GTGGTGGCTC TGAGGGTGGC GGTTCTGAGG 
     1861 GTGGCGGCTC TGAGGGAGGC GGTTCCGGTG GTGGCTCTGG TTCCGGTGAT TTTGATTATG 
     1921 AAAAGATGGC AAACGCTAAT AAGGGGGCTA TGACCGAAAA TGCCGATGAA AACGCGCTAC 
     1981 AGTCTGACGC TAAAGGCAAA CTTGATTCTG TCGCTACTGA TTACGGTGCT GCTATCGATG 
     2041 GTTTCATTGG TGACGTTTCC GGCCTTGCTA ATGGTAATGG TGCTACTGGT GATTTTGCTG 
     2101 GCTCTAATTC CCAAATGGCT CAAGTCGGTG ACGGTGATAA TTCACCTTTA ATGAATAATT 
     2161 TCCGTCAATA TTTACCTTCC CTCCCTCAAT CGGTTGAATG TCGCCCTTTT GTCTTTGGCG 
     2221 CTGGTAAACC ATATGAATTT TCTATTGATT GTGACAAAAT AAACTTATTC CGTGGTGTCT 
     2281 TTGCGTTTCT TTTATATGTT GCCACCTTTA TGTATGTATT TTCTACGTTT GCTAACATAC 
     2341 TGCGTAATAA GGAGTCTTAA GAAGACCCAG GCATCAAATA AAACGAAAGG CTCAGTCGAA 
     2401 AGACTGGGCC TTTCGTTTTA TCTGTTGTTT GTCGGTGAAC GCTCTCTACT AGAGTCACAC 
     2461 TGGCTCACCT TCGGGTGGGC CTTTCTGCGT TTATATATAC TTTAGATTGA TTTACCCCGG 
     2521 TTGATAATCA GAAAAGCCCC AAAAACAGGA AGATTGTATA AGCAAATATT TAAATTGTAA 
     2581 ACGTTAATAT TTTGTTAAAA TTCGCGTTAA ATTTTTGTTA AATCAGCTCA TTTTTTAACC 
     2641 AATAGGCCGA AATCGGCAAA ATCCCTTATA AATCAAAAGA ATAGCCCGAG ATAGGGTTGA 
     2701 GTGTTGTTCC AGTTTGGAAC AAGAGTCCAC TATTAAAGAA CGTGGACTCC AACGTCAAAG 
     2761 GGCGAAAAAC CGTCTATCAG GGCGATGGCC CACTACGTGA ACCATCACCC AAATCAAGTT 
     2821 TTTTGGGGTC GAGGTGCCGT AAAGCACTAA ATCGGAACCC TAAAGGGAGC CCCCGATTTA 
     2881 GAGCTTGACG GGGAAAGCGA ACGTGGCGAG AAAGGAAGGG AAGAAAGCGA AAGGAGCGGG 
     2941 CGCTAGGGCG CTGGCAAGTG TAGCGGTCAC GCTGCGCGTA ACCACCACAC CCGCCGCGCT 
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     3001 TAATGCGCCG CTACAGGGCG CGTAAAAGGA TCTAGGTGAA GATCCTTTTT GATAATCTCA 
     3061 TGACCAAAAT CCCTTAACGT GAGTTTTCGT TCCACTGAGC GTCAGACCCC GTAGAAAAGA 
     3121 TCAAAGGATC TTCTTGAGAT CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA 
     3181 AACCACCGCT ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA 
     3241 AGGTAACTGG CTTCAGCAGA GCGCAGATAC CAAATACTGT TCTTCTAGTG TAGCCGTAGT 
     3301 TAGGCCACCA CTTCAAGAAC TCTGTAGCAC CGCCTACATA CCTCGCTCTG CTAATCCTGT 
     3361 TACCAGTGGC TGCTGCCAGT GGCGATAAGT CGTGTCTTAC CGGGTTGGAC TCAAGACGAT 
     3421 AGTTACCGGA TAAGGCGCAG CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT 
     3481 TGGAGCGAAC GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCTATGA GAAAGCGCCA 
     3541 CGCTTCCCGA AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG 
     3601 AGCGCACGAG GGAGCTTCCA GGGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC 
     3661 GCCACCTCTG ACTTGAGCGT CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA 
     3721 AAAACGCCAG CAACGCGGCC TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA 
     3781 TGTAATGTGA GTTAGCTCAC TCATTAGAAT TCGCTGAGAG ACCCGTGCTG ATCACTGACC 
     3841 ACAACGTGCG TGAAACACTG GCGGTTTGTG AACGCGCTTA TATCGTCAGT CAGGGGCATT 
     3901 TGATCGCCCA CGGCACGCCT ACAGAAATCT TACAAGACGA ACACGTTAAG CGTGTATACC 
     3961 TTGGGGAAGA CTTCAGACTC TGATAGGGTA GAAGTTTGCG ACGTTTTAGC AGGAGAGTAC 
     4021 GATTCTGAAC ATGAGCACAA AAAAGAAACC ATTAACACAA GAGCAGCTTG AGGACGCACG 
     4081 TCGCCTTAAA GCAATTTATG AAAAAAAGAA AAATGAACTT GGCTTATCCC AGGAATTGGT 
     4141 CGCATACGAG ATGGGGATGG GGCAGTCCGC GGTTTCCGAG TTATTTAATG GCATCTGGGC 
     4201 ATTAAATGCT TATAACGCCG CATTGCTTGC AAAAATTCTC AAAGTTAGCG TTGAAGAATT 
     4261 TAGCCCTTCA ATCGCCAGAG AAATCTACGA GATGTATGAA GCGGTTAGTA TGCAGCCGTC 
     4321 ACTTAGAAGT GAGTATGAGT ACCCTGTTTT TTCTCATGTT CAGGCAGGGA TGTTCTCACC 
     4381 TGAGCTTAGA ACCTTTACCA AAGGTGATGC GGAGAGATGG GTAAGCACAA CCAAAAAAGC 
     4441 CAGTGATTCT GCATTCTGGC TTGAGGTTGA AGGTAATTCC ATGACCGCAC CAACAGGCTC 
     4501 CAAGCCAAGC TTTCCTGACG GAATGTTAAT TCTCGTTGAC CCTGAGCAGG CTGTTGAGCC 
     4561 AGGTGATTTC TGCATAGCCA GACTTGGGGG TGATGAGTTT ACCTTCAAGA AACTGATCAG 
     4621 GGATAGCGGT CAGGTGTTTT TACAACCACT AAACCCACAG TACCCAATGA TCCCATGCAA 
     4681 TGAGAGTTGT TCCGTTGTGG GGAAAGTTAT CGCTAGTCAG TGGCCTGAAG AGACGTTTGG 
     4741 CTGAGAAGAC CCAGGCATCA AATAAAACGA AAGGCTCAGT CGAAAGACTG GGCCTTTCGT 
     4801 TTTATCTGTT GTTTGTCGGT GAACGCTCTC TACTAGAGTC ACACTGGCTC ACCTTCGGGT 
     4861 GGGCCTTTCT GCGTTTATAG GTCTCCTGGC CTGCAGTAAA GCCCGCTTCG GCGGGCTTTT 




Supplementary Data 4. Sequence of the accessory plasmid (AP) pJPC12-ΔPS-PRM-
B0034-geneVI. Sequencing primers listed in Table 1 are underlined (pJPC12-F, pJPC12-R). 
The total plasmid size is 5,300 bp. The plasmid is available from Addgene (ID 80858). 
 
FEATURES             Location/Qualifiers 
     gene            complement (1..146 and 4783..5300) 
                     /label="Chloramphenicol resistance" 
     promoter        593..683 
                     /label="PRM" 
     RBS             684..695 
                     /label="BBa_B0034" 
     gene            702..1040 
                     /label="gene 6" 
     terminator      1041..1074 
                     /label="BBa_B1002" 
     origin          2794..3744 
                     /label="repA" 
 
        1 TTTACGGTCT TTAAAAAGGC CGTAATATCC AGCTGAACGG TCTGGTTATA GGTACATTGA 
       61 GCAACTGACT GAAATGCCTC AAAATGTTCT TTACGATGCC ATTGGGATAT ATCAACGGTG 
      121 GTATATCCAG TGATTTTTTT CTCCATTTTA GCTTCCTTAG CTCCTGAAAA TCTCGATAAC 
      181 TCAAAAAATA CGCCCGGTAG TGATCTTATT TCATTATGGT GAAAGTTGGA ACCTCTTACA 
      241 AAAGGATCTA GGTGAAGATC CTTTTTGATA ATCTCATGAG CGGATACATA TTTGAATGTA 
      301 TTTAGAAAAA TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCACCTTCAG 
      361 GCTGCGCAAC TGTTGGGAAG GGCGATCGGT GCGGGCCTCT TCGCTATTAC GCCAGCTGGC 
      421 GAAAGGGGGA TGTGCTGCAA GGCGATTAAG TTGGGTAACG CCAGGGTTTT CCCAGTCACG 
      481 ACGTTGTAAA ACGACGGCCA GTGAGCGCGC GTAATACGAC TCACTATAGG GCGAATTGGG 
      541 TACCGGGCCC CCCCTCGAGG TCGACGGTAT CGATAAGCTT GATATCGAAT TCGCAACCAT 
      601 TATCACCGCC AGAGGTAAAA TAGTCAACAC GCACGGTGTT AGATATTACA AACTTTCTTG 
      661 TATAGATTTA CAATGTATCT TGTAAAGAGG AGAAATACTA GATGCCAGTT CTTTTGGGTA 
      721 TTCCGTTATT ATTGCGTTTC CTCGGTTTCC TTCTGGTAAC TTTGTTCGGC TATCTGCTTA 
      781 CTTTTCTTAA AAAGGGCTTC GGTAAGATAG CTATTGCTAT TTCATTGTTT CTTGCTCTTA 
      841 TTATTGGGCT TAACTCAATT CTTGTGGGTT ATCTCTCTGA TATTAGCGCT CAATTACCCT 
      901 CTGACTTTGT TCAGGGTGTT CAGTTAATTC TCCCGTCTAA TGCGCTTCCC TGTTTTTATG 
      961 TTATTCTCTC TGTAAAGGCT GCTATTTTCA TTTTTGACGT TAAACAAAAA ATCGTTTCTT 
     1021 ATTTGGATTG GGATAAATAA CGCAAAAAAC CCCGCTTCGG CGGGGTTTTT TCGCAGCTCC 
     1081 AGCTTTTGTT CCCTTTAGTG AGGGTTAATT GCGCGCTTGG CGTAATCATG GTCATAGCTG 
     1141 TTTCCTGTGT GAAATTGTTA TCCGCTCACA ATTCCACACA ACATACGAGC CGGAAGCATA 
     1201 AAGTGTAAAG CCTGGGGTGC CTAATGAGTG AGCTAACTCA CATTAATTGC GTTGCGCTCA 
     1261 CTGCCCGCTT TCCAGTCGGG AAACCTGTCG TGCCAGCTGC ATTAATGAAT CGGCCAACGC 
     1321 GCGGGGAGAG GCGGTTTGCG TATTGGGCGC TCTTCCGCTT CCTCGCTCAC TGACTCGCTG 
     1381 CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA 
     1441 TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG ATCTCTACGG GTCGGATTTG 
     1501 AAGTCGTCTT GGTAGGAGGC AGCCTGAATG GCGAATGCCG ATGCCCTTGA GAGCCTTCAA 
     1561 CCCAGTCAGC TCCTTCCGGT GGGCGCGGGG CATGACTATC GTCGCCGCAC TTATGACTGT 
     1621 CTTCTTTATC ATGCAACTCG TAGGACAGGG TGCCGGCAGC GCTCTGGGTC ATTTTCGGCG 
     1681 AGGACCGCTT TCGCTGGAGC GCGACGATGA TCGGCCTGTC GCTTGCGGTA TTCGGAATCT 
     1741 TGCACGCCCT CGCTCAAGCC TTCGTCACTG GTCCCGCCAC CAAACGTTTC GGCGAGAAGC 
     1801 AGGCCATTAT CGCCGGCATG GCGGCCGACG CGCTGGGCTA CGTCTTGCTG GCGTTCGCGA 
     1861 CGCGAGGCTG GATGGCCTTC CCCATTATGA TTCTTCTCGC TTCCGGCGGC ATCGGGATGC 
     1921 CCGCGTTGCA GGCCATGCTG TCCAGGCAGG TAGATGACGA CCATCAGGGA CAGCTTCAAG 
     1981 GATCGCTCGC GGCTCTTACC AGCCTAACTT CGATCATTGG ACCGCTGATC GTCACGGCGA 
     2041 TTTATGCCGC CTCGGCGAGC ACATGGAACG GGTTGGCATG GATTGTAGGC GCCGCCCTAT 
     2101 ACCTTGTCTG CCTCCCCGCG TTGCGTCGCG GTGCATGGAG CCGGGCCACC TCGACCTGAA 
     2161 TGGAAGCCGG CGGCACCTCG CTAACGGATT CACCACTCCG CAGACCCGCC ATAAAACGCC 
     2221 CTGAGAAGCC CGTGACGGGC TTTTCTTGTA TTATGGGTAG TTTCCTTGCA TGAATCCATA 
     2281 AAAGGCGCCT GTAGTGCCAT TTACCCCCAT TCACTGCCAG AGCCGTGAGC GCAGCGAACT 
     2341 GAATGTCACG AAAAAGACAG CGACTCAGGT GCCTGATGGT CGGAGACAAA AGGAATATTC 
     2401 AGCGATTTGC CCGAGCTTGC GAGGGTGCTA CTTAAGCCTT TAGGGTTTTA AGGTCTGTTT 
     2461 TGTAGAGGAG CAAACAGCGT TTGCGACATC CTTTTGTAAT ACTGCGGAAC TGACTAAAGT 
     2521 AGTGAGTTAT ACACAGGGCT GGGATCTATT CTTTTTATCT TTTTTTATTC TTTCTTTATT 
     2581 CTATAAATTA TAACCACTTG AATATAAACA AAAAAAACAC ACAAAGGTCT AGCGGAATTT 
     2641 ACAGAGGGTC TAGCAGAATT TACAAGTTTT CCAGCAAAGG TCTAGCAGAA TTTACAGATA 
     2701 CCCACAACTC AAAGGAAAAG GACTAGTAAT TATCATTGAC TAGCCCATCT CAATTGGTAT 
     2761 AGTGATTAAA ATCACCTAGA CCAATTGAGA TGTATGTCTG AATTAGTTGT TTTCAAAGCA 
     2821 AATGAACTAG CGATTAGTCG CTATGACTTA ACGGAGCATG AAACCAAGCT AATTTTATGC 
     2881 TGTGTGGCAC TACTCAACCC CACGATTGAA AACCCTACAA GGAAAGAACG GACGGTATCG 
     2941 TTCACTTATA ACCAATACGC TCAGATGATG AACATCAGTA GGGAAAATGC TTATGGTGTA 
     3001 TTAGCTAAAG CAACCAGAGA GCTGATGACG AGAACTGTGG AAATCAGGAA TCCTTTGGTT 
     3061 AAAGGCTTTA AGATCTTCCA GTGGACAAAC TATGCCAAGT TCTCAAGCGA AAAATTAGAA 
     3121 TTAGTTTTTA GTGAAGAGAT ATTGCCTTAT CTTTTCCAGT TAAAAAAATT CATAAAATAT 
     3181 AATCTGGAAC ATGTTAAGTC TTTTGAAAAC AAATACTCTA TGAGGATTTA TGAGTGGTTA 
     3241 TTAAAAGAAC TAACACAAAA GAAAACTCAC AAGGCAAATA TAGAGATTAG CCTTGATGAA 
     3301 TTTAAGTTCA TGTTAATGCT TGAAAATAAC TACCATGAGT TTAAAAGGCT TAACCAATGG 
     3361 GTTTTGAAAC CAATAAGTAA AGATTTAAAC ACTTACAGCA ATATGAAATT GGTGGTTGAT 
     3421 AAGCGAGGCC GCCCGACTGA TACGTTGATT TTCCAAGTTG AACTAGATAG ACAAATGGAT 
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     3481 CTCGTAACCG AACTTGAGAA CAACCAGATA AAAATGAATG GTGACAAAAT ACCAACAACC 
     3541 ATTACATCAG ATTCCTACCT ACATAACGGA CTAAGAAAAA CACTACACGA TGCTTTAACA 
     3601 GCAAAAATTC AGCTCACCAG TTTTGAGGCA AAATTTTTGA GTGACATGCA AAGTAAGTAT 
     3661 GATCTCAATG GTTCGTTCTC ATGGCTCACG CAAAAACAAC GAACCACACT AGAGAACATA 
     3721 CTGGCTAAAT ACGGAAGGAT CTGAGGTTCT TATGGCTCTT GTATCTATCA GTGAAGCATC 
     3781 AAGACTAACA AACAAAAGTA GAACAACTGT TCACCGTTAC ATATCAAAGG GAAAACTGTC 
     3841 CATATGCACA GATGAAAACG GTGTAAAAAA GATAGATACA TCAGAGCTTT TACGAGTTTT 
     3901 TGGTGCATTC AAAGCTGTTC ACCATGAACA GATCGACAAT GTAACAGATG AACAGCATGT 
     3961 AACACCTAAT AAGAACAGGT GAAACCAGTA AAACAAAGCA ACTAGAACAT GAAATTGAAC 
     4021 ACCTGAGACA ACTTGTTACA GCTCAACAGT CACACATAGA CAGCCTGAAA CAGGCGATGC 
     4081 TGCTTATCGA ATCAAAGCTG CCGACAACAC GGGAGCCAGT GACGCCTCCC GTGGGGAAAA 
     4141 AATCATGGCA ATTCTGGAAG AAATAGCGCT TTCAGCCGGC AAACCGGCTG AAGCCGGATC 
     4201 TGCGATTCTG ATAACAAACT AGCAACACCA GAACAGCCCG TTTGCGGGCA GCAAAACCCG 
     4261 TACTTTTGGA CGTTCCGGCG GTTTTTTGTG GCGAGTGGTG TTCGGGCGGT GCGCGCAAGA 
     4321 TCCATTATGT TAAACGGGCG AGTTTACATC TCAAAACCGC CCGCTTAACA CCATCAGAAA 
     4381 TCCTCAGCGC GATTTTAAGC ACCAACCCCC CCCCGTAACA CCCAAATCCA TACTGAAAGT 
     4441 GGCTTTGTTG AATAAATCAG ATTTCGGGTA AGTCTCCCCC GTAGCGGGTT GTGTTTTCAG 
     4501 GCAATACGCA CGCTTTCAGG CATACCTGCT TTCGTCATTT TGTTCAGCGC TCGTACCAGG 
     4561 GCCATAGCCT CCGCAACCTG ACCATCGTAG TCACGCAGCG TCAGTGAACC CCCGAACAGA 
     4621 GATCTGACGC TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGACAATAAC 
     4681 CCTGATAAAT GCTTCAATAA TCGCAGACCA AAACGATCTC AAGAAGATCA TCTTATTAAT 
     4741 CAGATAAAAT ATTTCTAGGC ACCAATAACT GCCTTAAAAA AATTACGCCC CGCCCTGCCA 
     4801 CTCATCGCAG TACTGTTGTA ATTCATTAAG CATTCTGCCG ACATGGAAGC CATCACAAAC 
     4861 GGCATGATGA ACCTGAATCG CCAGCGGCAT CAGCACCTTG TCGCCTTGCG TATAATATTT 
     4921 GCCCATGGTG AAAACGGGGG CGAAGAAGTT GTCCATATTG GCCACGTTTA AATCAAAACT 
     4981 GGTGAAACTC ACCCAGGGAT TGGCTGAAAC GAAAAACATA TTCTCAATAA ACCCTTTTAG 
     5041 GGAAATAAGG CCAGGTTTTC ACCGTAACAC GCCACATCTT GGGAAATATT TGTGTAGAAA 
     5101 CTGCCGGAAA TCGTCGTGGT ATTCACTCCA GAGCGATGAA AACGTTTCAG TTTGCTCATG 
     5161 GAAAACGGTG TAACAAGGGT GAACACTATC CCATATCACC AGCTCACCGT CTTTCATTGC 
     5221 CATACGAAAT TCCGGATGAG CATTCATCAG GCGGGCAAGA ATGTGAATAA AGGCCGGATA 





Supplementary Data 5. Sequence of the reporter plasmid (RP) pJPC12-ΔPS-mCherry-
PR/PRM-GFP. The sequencing primer listed in Table 1 is underlined (pJPC12-F2). The total 
plasmid size is 6,238 bp. The plasmid is available from Addgene (ID 80859). 
 
FEATURES             Location/Qualifiers 
     gene            complement (1..146 and 4783..5300) 
                     /label="Chloramphenicol resistance" 
     terminator      complement(593..697) 
                     /label=T1 
     gene            complement(709..1419) 
                     /label=mCherry 
     RBS             complement(1426..1437) 
                     /label=BBa_B0034 
     promoter        1446..1524 
                     /label="PRM" 
     RBS             1531..1542 
                     /label="BBa_B0034" 
     gene            1549..2265 
                     /label=GFP 
     terminator      2266..2299 
                     /label="BBa_B1002" 
     origin          3732..4682 
                     /label="repA" 
 
        1 TTTACGGTCT TTAAAAAGGC CGTAATATCC AGCTGAACGG TCTGGTTATA GGTACATTGA 
       61 GCAACTGACT GAAATGCCTC AAAATGTTCT TTACGATGCC ATTGGGATAT ATCAACGGTG 
      121 GTATATCCAG TGATTTTTTT CTCCATTTTA GCTTCCTTAG CTCCTGAAAA TCTCGATAAC 
      181 TCAAAAAATA CGCCCGGTAG TGATCTTATT TCATTATGGT GAAAGTTGGA ACCTCTTACA 
      241 AAAGGATCTA GGTGAAGATC CTTTTTGATA ATCTCATGAG CGGATACATA TTTGAATGTA 
      301 TTTAGAAAAA TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCACCTTCAG 
      361 GCTGCGCAAC TGTTGGGAAG GGCGATCGGT GCGGGCCTCT TCGCTATTAC GCCAGCTGGC 
      421 GAAAGGGGGA TGTGCTGCAA GGCGATTAAG TTGGGTAACG CCAGGGTTTT CCCAGTCACG 
      481 ACGTTGTAAA ACGACGGCCA GTGAGCGCGC GTAATACGAC TCACTATAGG GCGAATTGGG 
      541 TACCGGGCCC CCCCTCGAGG TCGACGGTAT CGATAAGCTT GATATCGAAT TCGTCTAGGG 
      601 CGGCGGATTT GTCCTACTCA GGAGAGCGTT CACCGACAAA CAACAGATAA AACGAAAGGC 
      661 CCAGTCTTTC GACTGAGCCT TTCGTTTTAT TTGATGCCTC TACTCGAGTT ACTTGTACAG 
      721 CTCGTCCATG CCGCCGGTGG AGTGGCGGCC CTCGGCGCGT TCGTACTGTT CCACGATGGT 
      781 GTAGTCCTCG TTGTGGGAGG TGATGTCCAA CTTGATGTTG ACGTTGTAGG CGCCGGGCAG 
      841 CTGCACGGGC TTCTTGGCCT TGTAGGTGGT CTTGACCTCA GCGTCGTAGT GGCCGCCGTC 
      901 CTTCAGCTTC AGCCTCTGCT TGATCTCGCC CTTCAGGGCG CCGTCCTCGG GGTACATCCG 
      961 CTCGGAGGAG GCCTCCCAGC CCATAGTCTT CTTCTGCATT ACGGGGCCGT CGGAGGGGAA 
     1021 GTTGGTGCCG CGCAGCTTCA CCTTGTAGAT GAACTCGCCG TCCTGCAGGG AGGAGTCCTG 
     1081 GGTCACGGTC ACCACGCCGC CGTCCTCGAA GTTCATCACG CGCTCCCACT TGAAGCCCTC 
     1141 GGGGAAGGAC AGCTTCAAGT AGTCGGGGAT GTCGGCGGGG TGCTTCACGT AGGCCTTGGA 
     1201 GCCGTACATG AACTGAGGGG ACAGGATGTC CCAGGCGAAG GGCAGGGGGC CACCCTTGGT 
     1261 CACCTTCAGC TTGGCGGTCT GGGTGCCCTC GTAGGGGCGG CCCTCGCCCT CGCCCTCGAT 
     1321 CTCGAACTCG TGGCCGTTCA CGGAGCCCTC CATGTGCACC TTGAAGCGCA TGAACTCCTT 
     1381 GATGATAGCC ATGTTATCCT CCTCGCCCTT GCTCACCATG AATTCTTTCT CCTCTTTGCA 
     1441 ACCATTATCA CCGCCAGAGG TAAAATAGTC AACACGCACG GTGTTAGATA TTTATAAATA 
     1501 GTGGTGATAG ATTTAACGTT ACTAGAGATT AAAGAGGAGA AATACTAGAT GCGTAAAGGC 
     1561 GAAGAACTGT TTACCGGTGT GGTTCCGATT CTGGTGGAAC TGGACGGCGA TGTTAATGGT 
     1621 CATAAATTCA GTGTTCGCGG CGAAGGTGAA GGCGATGCGA CGAACGGCAA ACTGACCCTG 
     1681 AAATTTATCT GCACCACGGG TAAACTGCCG GTCCCGTGGC CGACGCTGGT GACCACGCTG 
     1741 ACCTATGGCG TTCAATGTTT TGCGCGTTAC CCGGATCACA TGAAACAGCA CGACTTTTTC 
     1801 AAATCGGCCA TGCCGGAAGG CTATGTGCAG GAACGTACGA TTAGCTTTAA AGACGATGGT 
     1861 ACGTATAAAA CCCGCGCGGA AGTGAAATTC GAAGGCGATA CCCTGGTTAA CCGTATCGAA 
     1921 CTGAAAGGTA TCGATTTCAA AGAAGACGGC AATATTCTGG GTCATAAACT GGAATATAAC 
     1981 TTCAATTCCC ACAACGTGTA CATCACCGCG GATAAACAGA AAAACGGCAT TAAAGCCAAT 
     2041 TTCAAAATCC GCCATAATGT GGAAGATGGT AGCGTTCAGC TGGCCGACCA CTATCAGCAA 
     2101 AACACGCCGA TTGGTGATGG CCCGGTCCTG CTGCCGGACA ATCACTACCT GAGTACCCAG 
     2161 TCCGTGCTGT CAAAAGATCC GAACGAAAAA CGTGACCACA TGGTCCTGCT GGAATTTGTG 
     2221 ACGGCTGCGG GTATCACCCA CGGCATGGAC GAACTGTATA AATAACGCAA AAAACCCCGC 
     2281 TTCGGCGGGG TTTTTTCGCC TCGCTCACTG ACTCGCTGCG CTCGGTCGTT CGGCTGCGGC 
     2341 GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC CACAGAATCA GGGGATAACG 
     2401 CAGGAAAGAA CATGTGAGAT CTCTACGGGT CGGATTTGAA GTCGTCTTGG TAGGAGGCAG 
     2461 CCTGAATGGC GAATGCCGAT GCCCTTGAGA GCCTTCAACC CAGTCAGCTC CTTCCGGTGG 
     2521 GCGCGGGGCA TGACTATCGT CGCCGCACTT ATGACTGTCT TCTTTATCAT GCAACTCGTA 
     2581 GGACAGGGTG CCGGCAGCGC TCTGGGTCAT TTTCGGCGAG GACCGCTTTC GCTGGAGCGC 
     2641 GACGATGATC GGCCTGTCGC TTGCGGTATT CGGAATCTTG CACGCCCTCG CTCAAGCCTT 
     2701 CGTCACTGGT CCCGCCACCA AACGTTTCGG CGAGAAGCAG GCCATTATCG CCGGCATGGC 
     2761 GGCCGACGCG CTGGGCTACG TCTTGCTGGC GTTCGCGACG CGAGGCTGGA TGGCCTTCCC 
     2821 CATTATGATT CTTCTCGCTT CCGGCGGCAT CGGGATGCCC GCGTTGCAGG CCATGCTGTC 
     2881 CAGGCAGGTA GATGACGACC ATCAGGGACA GCTTCAAGGA TCGCTCGCGG CTCTTACCAG 
     2941 CCTAACTTCG ATCATTGGAC CGCTGATCGT CACGGCGATT TATGCCGCCT CGGCGAGCAC 
     3001 ATGGAACGGG TTGGCATGGA TTGTAGGCGC CGCCCTATAC CTTGTCTGCC TCCCCGCGTT 
     3061 GCGTCGCGGT GCATGGAGCC GGGCCACCTC GACCTGAATG GAAGCCGGCG GCACCTCGCT 
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     3121 AACGGATTCA CCACTCCGCA GACCCGCCAT AAAACGCCCT GAGAAGCCCG TGACGGGCTT 
     3181 TTCTTGTATT ATGGGTAGTT TCCTTGCATG AATCCATAAA AGGCGCCTGT AGTGCCATTT 
     3241 ACCCCCATTC ACTGCCAGAG CCGTGAGCGC AGCGAACTGA ATGTCACGAA AAAGACAGCG 
     3301 ACTCAGGTGC CTGATGGTCG GAGACAAAAG GAATATTCAG CGATTTGCCC GAGCTTGCGA 
     3361 GGGTGCTACT TAAGCCTTTA GGGTTTTAAG GTCTGTTTTG TAGAGGAGCA AACAGCGTTT 
     3421 GCGACATCCT TTTGTAATAC TGCGGAACTG ACTAAAGTAG TGAGTTATAC ACAGGGCTGG 
     3481 GATCTATTCT TTTTATCTTT TTTTATTCTT TCTTTATTCT ATAAATTATA ACCACTTGAA 
     3541 TATAAACAAA AAAAACACAC AAAGGTCTAG CGGAATTTAC AGAGGGTCTA GCAGAATTTA 
     3601 CAAGTTTTCC AGCAAAGGTC TAGCAGAATT TACAGATACC CACAACTCAA AGGAAAAGGA 
     3661 CTAGTAATTA TCATTGACTA GCCCATCTCA ATTGGTATAG TGATTAAAAT CACCTAGACC 
     3721 AATTGAGATG TATGTCTGAA TTAGTTGTTT TCAAAGCAAA TGAACTAGCG ATTAGTCGCT 
     3781 ATGACTTAAC GGAGCATGAA ACCAAGCTAA TTTTATGCTG TGTGGCACTA CTCAACCCCA 
     3841 CGATTGAAAA CCCTACAAGG AAAGAACGGA CGGTATCGTT CACTTATAAC CAATACGCTC 
     3901 AGATGATGAA CATCAGTAGG GAAAATGCTT ATGGTGTATT AGCTAAAGCA ACCAGAGAGC 
     3961 TGATGACGAG AACTGTGGAA ATCAGGAATC CTTTGGTTAA AGGCTTTAAG ATCTTCCAGT 
     4021 GGACAAACTA TGCCAAGTTC TCAAGCGAAA AATTAGAATT AGTTTTTAGT GAAGAGATAT 
     4081 TGCCTTATCT TTTCCAGTTA AAAAAATTCA TAAAATATAA TCTGGAACAT GTTAAGTCTT 
     4141 TTGAAAACAA ATACTCTATG AGGATTTATG AGTGGTTATT AAAAGAACTA ACACAAAAGA 
     4201 AAACTCACAA GGCAAATATA GAGATTAGCC TTGATGAATT TAAGTTCATG TTAATGCTTG 
     4261 AAAATAACTA CCATGAGTTT AAAAGGCTTA ACCAATGGGT TTTGAAACCA ATAAGTAAAG 
     4321 ATTTAAACAC TTACAGCAAT ATGAAATTGG TGGTTGATAA GCGAGGCCGC CCGACTGATA 
     4381 CGTTGATTTT CCAAGTTGAA CTAGATAGAC AAATGGATCT CGTAACCGAA CTTGAGAACA 
     4441 ACCAGATAAA AATGAATGGT GACAAAATAC CAACAACCAT TACATCAGAT TCCTACCTAC 
     4501 ATAACGGACT AAGAAAAACA CTACACGATG CTTTAACAGC AAAAATTCAG CTCACCAGTT 
     4561 TTGAGGCAAA ATTTTTGAGT GACATGCAAA GTAAGTATGA TCTCAATGGT TCGTTCTCAT 
     4621 GGCTCACGCA AAAACAACGA ACCACACTAG AGAACATACT GGCTAAATAC GGAAGGATCT 
     4681 GAGGTTCTTA TGGCTCTTGT ATCTATCAGT GAAGCATCAA GACTAACAAA CAAAAGTAGA 
     4741 ACAACTGTTC ACCGTTACAT ATCAAAGGGA AAACTGTCCA TATGCACAGA TGAAAACGGT 
     4801 GTAAAAAAGA TAGATACATC AGAGCTTTTA CGAGTTTTTG GTGCATTCAA AGCTGTTCAC 
     4861 CATGAACAGA TCGACAATGT AACAGATGAA CAGCATGTAA CACCTAATAA GAACAGGTGA 
     4921 AACCAGTAAA ACAAAGCAAC TAGAACATGA AATTGAACAC CTGAGACAAC TTGTTACAGC 
     4981 TCAACAGTCA CACATAGACA GCCTGAAACA GGCGATGCTG CTTATCGAAT CAAAGCTGCC 
     5041 GACAACACGG GAGCCAGTGA CGCCTCCCGT GGGGAAAAAA TCATGGCAAT TCTGGAAGAA 
     5101 ATAGCGCTTT CAGCCGGCAA ACCGGCTGAA GCCGGATCTG CGATTCTGAT AACAAACTAG 
     5161 CAACACCAGA ACAGCCCGTT TGCGGGCAGC AAAACCCGTA CTTTTGGACG TTCCGGCGGT 
     5221 TTTTTGTGGC GAGTGGTGTT CGGGCGGTGC GCGCAAGATC CATTATGTTA AACGGGCGAG 
     5281 TTTACATCTC AAAACCGCCC GCTTAACACC ATCAGAAATC CTCAGCGCGA TTTTAAGCAC 
     5341 CAACCCCCCC CCGTAACACC CAAATCCATA CTGAAAGTGG CTTTGTTGAA TAAATCAGAT 
     5401 TTCGGGTAAG TCTCCCCCGT AGCGGGTTGT GTTTTCAGGC AATACGCACG CTTTCAGGCA 
     5461 TACCTGCTTT CGTCATTTTG TTCAGCGCTC GTACCAGGGC CATAGCCTCC GCAACCTGAC 
     5521 CATCGTAGTC ACGCAGCGTC AGTGAACCCC CGAACAGAGA TCTGACGCTC AGTGGAACGA 
     5581 AAACTCACGT TAAGGGATTT TGGTCATGAG ACAATAACCC TGATAAATGC TTCAATAATC 
     5641 GCAGACCAAA ACGATCTCAA GAAGATCATC TTATTAATCA GATAAAATAT TTCTAGGCAC 
     5701 CAATAACTGC CTTAAAAAAA TTACGCCCCG CCCTGCCACT CATCGCAGTA CTGTTGTAAT 
     5761 TCATTAAGCA TTCTGCCGAC ATGGAAGCCA TCACAAACGG CATGATGAAC CTGAATCGCC 
     5821 AGCGGCATCA GCACCTTGTC GCCTTGCGTA TAATATTTGC CCATGGTGAA AACGGGGGCG 
     5881 AAGAAGTTGT CCATATTGGC CACGTTTAAA TCAAAACTGG TGAAACTCAC CCAGGGATTG 
     5941 GCTGAAACGA AAAACATATT CTCAATAAAC CCTTTTAGGG AAATAAGGCC AGGTTTTCAC 
     6001 CGTAACACGC CACATCTTGG GAAATATTTG TGTAGAAACT GCCGGAAATC GTCGTGGTAT 
     6061 TCACTCCAGA GCGATGAAAA CGTTTCAGTT TGCTCATGGA AAACGGTGTA ACAAGGGTGA 
     6121 ACACTATCCC ATATCACCAG CTCACCGTCT TTCATTGCCA TACGAAATTC CGGATGAGCA 
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